WO2021034080A1 - Composition for prevention or treatment of allergic disease or atopic dermatitis comprising carvone or salt thereof as active ingredient - Google Patents

Composition for prevention or treatment of allergic disease or atopic dermatitis comprising carvone or salt thereof as active ingredient Download PDF

Info

Publication number
WO2021034080A1
WO2021034080A1 PCT/KR2020/010976 KR2020010976W WO2021034080A1 WO 2021034080 A1 WO2021034080 A1 WO 2021034080A1 KR 2020010976 W KR2020010976 W KR 2020010976W WO 2021034080 A1 WO2021034080 A1 WO 2021034080A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
atopic dermatitis
active ingredient
weight
prevention
Prior art date
Application number
PCT/KR2020/010976
Other languages
French (fr)
Korean (ko)
Inventor
박태선
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Publication of WO2021034080A1 publication Critical patent/WO2021034080A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q13/00—Formulations or additives for perfume preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds

Definitions

  • the present invention relates to a composition for the prevention or treatment of allergic diseases or atopic dermatitis, comprising carbon (Carvone) or a salt thereof as an active ingredient.
  • Atopy is derived from the ancient Greek word'atopia', which means'strange, abnormal'.
  • Cooke and Coca first began to refer to a tendency that could genetically trigger a specific immune antibody response to an allergen, called atopy. With a steadily increasing trend worldwide, the incidence rate is increasing in developed countries with industrial development.
  • atopy The cause of the onset of atopy has not been accurately identified yet, but is not limited to one factor such as family history, changes in diet, penetration of allergens, and abnormal skin barriers. It occurs mainly in infancy and infancy, and may persist or begin in adulthood. Typical symptoms of atopy appear on the hands, scalp, face, neck, and elbows, but there are differences in the patterns that appear by period. Symptoms of infancy are rough skin and dryness, dermatitis on the outside of limbs, cheeks and foreheads, and sores or scabs sit after scratching with hands. In childhood, it mainly appears on the folds of arms, legs and neck rather than the face, and the skin becomes dry. In puberty and adulthood, symptoms of thickening of the skin on areas such as the face and hands appear.
  • Topical steroids are used when atopic symptoms are severe and are the most basic method to manage bacterial or viral infections.
  • steroids have been introduced in 1950 and have been used for many years, but long-term use is restricted due to problems of skin safety and tolerance depending on the frequency, concentration, and duration of use.
  • potential skin side effects such as skin, atrophy, telangiectasia, and steroid acne, as well as inhibition of hypohalamic-pituitary-adrenal (HPA), and Cushing's syndrome. Sufficient care should be taken when using it as it may cause side effects.
  • HPA hypohalamic-pituitary-adrenal
  • the local immunomodulators tacrolimus and pimecrolimus are known to be used over a long period of time for the purpose of preventing recurrence of lesions as they have a relatively low possibility of side effects even when used for a long time, unlike conventional topical steroids. It is suitable for use as a treatment and maintenance therapy. However, tacrolimus may have side effects such as decreased kidney function, hand tremor, and hair loss, and pimecrolimus may have serious side effects such as acne and burning as well as skin cancer and lymphoma. When steroids worsen in the acute phase, local immunomodulators are suitable for use as treatment and maintenance therapy for mild atopy, but safety against side effects has not yet been secured, so there is an urgent need for alternative supplements.
  • the applicant of the present invention has made efforts to develop a material that has few side effects and is effective in relieving atopic dermatitis symptoms, and as a result, confirming that Carvone relieves atopic symptoms and improves the inflammatory response. Completed.
  • Another object of the present invention is to provide a composition for the prevention or improvement of allergic diseases or atopic dermatitis comprising carbon or a salt thereof as an active ingredient.
  • the present invention is to solve the above-described problems, and provides a pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis, comprising as an active ingredient carboxylic (Carvone) or a pharmaceutically acceptable salt thereof.
  • carboxylic Carvone
  • the allergic disease is edema, anaphylaxis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, contact It may be selected from the group consisting of sexual dermatitis, urticaria, pruritus, insect allergy, food allergy and drug allergy, but is not limited thereto.
  • the active ingredient expresses IL-4 (Interleukin-4), IL-13, TNF- ⁇ (tumor necrosis factor-alpha), IL-1 ⁇ , IL-6, or IL-8.
  • IL-4 Interleukin-4
  • IL-13 TNF- ⁇ (tumor necrosis factor-alpha)
  • TNF- ⁇ tumor necrosis factor-alpha
  • IL-1 ⁇ IL-6
  • IL-8 IL-8
  • the present invention provides a quasi-drug composition for the prevention or improvement of allergic diseases or atopic dermatitis comprising carbon or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention provides a cosmetic composition for the prevention or improvement of allergic diseases or atopic dermatitis comprising carbon or a cosmetically acceptable salt thereof as an active ingredient.
  • the present invention provides a perfume composition for the prevention or improvement of allergic diseases or atopic dermatitis, comprising carbon or a cosmetically acceptable salt thereof as an active ingredient.
  • the present invention provides a health functional food composition for the prevention or improvement of allergic diseases or atopic dermatitis, comprising as an active ingredient carbonyl or a food acceptable salt thereof.
  • the present invention provides a method for preventing or treating allergic diseases or atopic dermatitis, comprising administering or taking a composition comprising carbon or a pharmaceutically acceptable salt thereof as an active ingredient to an individual.
  • the present invention provides a use of a composition comprising carbon or a pharmaceutically acceptable salt thereof as an active ingredient to prevent or treat allergic diseases or atopic dermatitis.
  • composition comprising the carboxylic acid of the present invention as an active ingredient has an effect of improving atopic dermatitis due to an allergic reaction, and can be used as a composition for preventing or treating (improving) various allergic diseases by reducing the inflammatory response.
  • FIG. 1 is a graph showing the change in the secretion amount of histamine in mast cells (RBL-2H3 cells) treated with Carvone (each value is the mean ⁇ SEM of three times obtained from three independent wells; on a bar) Letters show a statistically significant difference at P ⁇ 0.05).
  • IL-4, IL-13 and TNF- ⁇ inflammatory cytokine-related molecules
  • Carvone each value is obtained from three independent wells. Mean ⁇ SEM of one trip; the letters on the bars represent statistically significant differences at P ⁇ 0.05).
  • 3 is a graph showing changes in the expression of inflammatory cytokine-related molecules (IL-1 ⁇ , IL-6 and IL-8) in keratinocytes treated with Carvone (each value is from 3 independent wells. Means of 3 obtained ⁇ SEM; letters on the bars show statistically significant differences at P ⁇ 0.05).
  • the present inventors found that carbon relieves atopic symptoms and expresses IL-4, IL-13, TNF- ⁇ , IL-1 ⁇ , IL-6, or IL-8, which are inflammatory cytokines secreted due to the immune response of cells. By confirming that the amount of secretion of histamine was significantly reduced and the amount of histamine was decreased, the present invention was completed.
  • the present invention provides a composition for preventing or treating (improving) allergic diseases or atopic dermatitis, comprising carbon (Carvone) or a salt thereof as an active ingredient.
  • the carvone is a terpenoid-based compound, and the IUPAC name is 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-ene- 1-one (2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one).
  • the chemical formula of carbon is C 10 H 14 O, the molecular weight is 150.2 g/mol, and the structure is as shown in [Chemical Formula 1] (molecular structure of carvone). Carbon is a colorless or pale yellow transparent liquid and is soluble in water, alcohol, chloroform ether, etc., but not in glycerol.
  • Carbon is known to be a safe edible substance, and has been approved as a flavor agent by EFSA (European Food Safety Athority) and JECFA (Joint FAO/WHO Expert Committee on Food Additives), and industrially has taste and aroma. It has been used for betting purposes.
  • EFSA European Food Safety Athority
  • JECFA Joint FAO/WHO Expert Committee on Food Additives
  • the carbon of the present invention may include a carboxylic hydrate, a carboxylic derivative, and the like within a range having the same efficacy as the carbon, and may also include a solvate or stereoisomer thereof.
  • the method for obtaining the carbon is not particularly limited, and may be isolated from a plant containing the carbon, chemically synthesized using a known manufacturing method, or a commercially available one may be used.
  • the carbon may be d-carvone (d-Carvone, Formula 2 below).
  • the term “cosmetically acceptable salt”, “food pharmaceutically acceptable salt”, “pharmaceutically acceptable salt” or “salt thereof” may be an acid addition salt formed by a free acid.
  • the acid addition salt can be prepared by a conventional method, for example, dissolving the compound in an excess aqueous acid solution, and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile.
  • a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile.
  • the same molar amount of the compound and an acid or alcohol (eg, glycol monomethyl ether) in water may be heated, and then the mixture may be evaporated to dryness, or the precipitated salt may be suction filtered.
  • an inorganic acid or an organic acid may be used as the free acid.
  • the inorganic acid may be hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, and the like, which may be used alone or in combination of two or more.
  • the organic acid include methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid (propionic acid).
  • the carbon can be made cosmetically or food acceptable metal salt using a base.
  • the alkali metal or alkaline earth metal salt can be obtained, for example, by dissolving the compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate.
  • the metal salt it is particularly preferable to prepare a sodium, potassium or calcium salt, but is not limited thereto.
  • the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (eg, silver nitrate).
  • the salt of the carboxylic may include all salts of acidic or basic groups that may be present in the compound of the carboxylic.
  • the salt of the carboxylic acid may include sodium, calcium and potassium salts of the hydroxy group, and other cosmetically acceptable salts of the amino group include hard bromide, sulfuric acid, hydrogen sulfate, phosphate, hydrogen phosphate , Dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts, and the like, and salts known in the art It can be manufactured through a manufacturing method.
  • allergic disease refers to a disease caused by an allergy reaction in which the body's immune response to an external antigen is excessive, and specifically, edema, hypersensitivity (anaphylaxis), allergic rhinitis (allergic) rhinitis), asthma, allergic conjunctivitis, allergic dermatitis, contact dermatitis, urticaria, pruritus, insect allergy, food allergy, and drug allergy.
  • edema hypersensitivity (anaphylaxis)
  • allergic rhinitis Allergic rhinitis
  • asthma allergic conjunctivitis
  • allergic dermatitis allergic dermatitis
  • contact dermatitis contact dermatitis
  • urticaria pruritus
  • pruritus insect allergy
  • food allergy food allergy
  • atopic dermatitis is one of allergic diseases and is a skin disease accompanied by symptoms such as itching, dry skin, increased skin thickness, and characteristic eczema.
  • the pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis is not particularly limited in its content as long as it contains carbonyl or a pharmaceutically acceptable salt thereof, but preferably the dose of carboxylic is 0.1 It may be included in a concentration of ⁇ M to 1000 ⁇ M, but is not limited thereto. At this time, if the carbon is less than the above concentration range, there is a problem that it is difficult to exert a desirable preventive or therapeutic effect, and if the carbon exceeds the above concentration range, there may be concerns of toxicity including cytotoxicity.
  • the pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis according to a conventional method, respectively, oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and It may be formulated and used in the form of a sterile injectable solution, and may include a suitable carrier, excipient, or diluent commonly used in the preparation of pharmaceutical compositions for formulation.
  • lactose As the carrier or excipient or diluent, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, undecided And various compounds or mixtures including vaginal cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
  • formulation it can be prepared using diluents or excipients such as fillers, weight agents, binders, wetting agents, disintegrants, and surfactants that are usually used.
  • diluents or excipients such as fillers, weight agents, binders, wetting agents, disintegrants, and surfactants that are usually used.
  • Solid preparations for oral administration may be prepared by mixing the carbon with at least one excipient, such as starch, calcium bonate, sucrose or lactose, gelatin, and the like.
  • excipients such as starch, calcium bonate, sucrose or lactose, gelatin, and the like.
  • lubricants such as magnesium stearate and talc can also be used.
  • Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc.
  • various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. may be included. .
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous agents, suspensions, emulsions, lyophilized formulations, and suppositories.
  • non-aqueous solvent and suspension propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
  • injectable ester such as ethyl oleate
  • a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerol gelatin, and the like can be used.
  • the preferred dosage of the pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis varies depending on the patient's condition, weight, degree of disease, drug form, route and duration of administration, but may be appropriately selected by those skilled in the art. I can. However, for a desirable effect, it may be administered at 0.0001 to 2,000 mg/kg per day, preferably 0.001 to 2,000 mg/kg. Administration may be administered once a day, or may be divided several times. However, the scope of the present invention is not limited by the dosage.
  • the pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis can be administered to mammals such as mice, mice, livestock, and humans by various routes. All modes of administration can be administered by, for example, oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
  • composition comprising the active ingredient according to the present invention reduces the expression of IL-4, IL-13, TNF- ⁇ , IL-1 ⁇ , IL-6, or IL-8 that is excessively secreted due to an immune response, or By reducing the amount of secretion, allergic diseases or atopic dermatitis symptoms can be improved and prevented.
  • Histamine a representative itching mediator, was proposed by Lewis in 1927 to cause itching in inflammatory skin diseases.
  • the main source of histamine in the skin is mast cells, and histamine, which is synthesized and stored, is secreted in response to stimulation.
  • the secreted histamine causes erythema, pain, vasodilation and swelling due to direct action on blood vessels and release of neuropeptide from sensory nerves in addition to itching through histamine receptors present in keratinocytes.
  • the inflammatory cytokines IL-4, IL-13, TNF- ⁇ , IL-1 ⁇ , IL-6 and IL-8 secreted by the immune response of cells
  • the inflammatory cytokines IL-4, IL-13, TNF- ⁇ , IL-1 ⁇ , IL-6 and IL-8 secreted by the immune response of cells
  • the present invention provides a composition for preventing or improving allergic diseases or atopic dermatitis, including carvone or a salt thereof as an active ingredient.
  • the specific content of the carbon is as described above.
  • the composition for preventing or improving allergic diseases or atopic dermatitis of the present invention may be a health functional food composition, a cosmetic composition, a perfume composition, or a quasi-drug composition.
  • the term "health functional food” refers to a food manufactured and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functions for the human body.
  • “functionality” means obtaining useful effects for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body.
  • the health functional food of the present invention can be prepared by a method commonly used in the art, and at the time of manufacture, it can be prepared by adding raw materials and ingredients commonly added in the art.
  • the formulation of the health functional food may be prepared without limitation as long as it is a formulation recognized as a health functional food.
  • the health functional food composition of the present invention has the advantage of not having side effects that may occur when taking the drug for a long period of time, unlike general drugs, using food as a raw material, and is excellent in portability, enhancing the anti-allergic effect or the relief effect of atopic dermatitis symptoms. It can be ingested as a supplement to make.
  • the carbon when used as an additive of a health functional food, it can be added as it is or used with other foods or food ingredients, and is usually It can be used appropriately according to the method of phosphorus.
  • the mixing amount of the active ingredient can be appropriately determined according to each purpose of use, such as prevention, health or treatment.
  • Formulations of health functional foods may be in the form of powders, granules, pills, tablets, capsules, as well as general foods or beverages.
  • the type of food is not particularly limited, and examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, and dairy products including ice cream. , Various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes, and may include all foods in the usual sense.
  • the carbon when preparing food or beverage, may be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on 100 parts by weight of the raw material.
  • the amount in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the amount may be less than the above range, and the present invention has no problem in terms of safety in terms of using fractions from natural products. It can also be used in the above amount.
  • the beverage may contain various flavoring agents or natural carbohydrates as an additional component, like a conventional beverage.
  • the natural carbohydrates described above may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • sweetener natural sweeteners such as taumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used.
  • the ratio of the natural carbohydrate may be about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the beverage according to the present invention.
  • the health functional food for the prevention or improvement of allergic diseases or atopic dermatitis includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloids. It may contain thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages.
  • the health functional food composition for preventing or improving allergic diseases or atopic dermatitis of the present invention may contain flesh for the manufacture of natural fruit juice, fruit juice drink, and vegetable drink. These ingredients may be used independently or in combination. The ratio of these additives is not limited, but it is generally selected from 0.01 to 0.1 parts by weight based on 100 parts by weight of the functional food of the present invention.
  • cosmetic composition used in the present invention is a composition including the compound, and the formulation may be in any form.
  • cosmetic products prepared using the above composition include creams such as nutritional cream, eye cream, massage cream, cleansing cream, packs, lotions such as nutritional lotion, essences, softening lotion, lotion such as nutritional lotion.
  • lotions such as nutritional lotion, essences, softening lotion
  • lotion such as nutritional lotion.
  • Types, powders, foundations, makeup bases, and the like and can be manufactured and commercialized in any of these formulations to achieve the object of the present invention, and are not limited to the above examples.
  • the cosmetic composition according to the present invention can be formulated by a conventional cosmetic preparation method.
  • the cosmetics of the present invention are skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, pack, mask pack, mask sheet , Soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, press powder, loose powder, and eye shadow.It may have any one formulation selected from the group consisting of.
  • the cosmetic composition of the present invention may contain other additives such as excipients, carriers, etc. in addition to carbon or salts thereof, and it is possible to apply and mix ordinary ingredients to be blended in general skin cosmetics as needed.
  • the cosmetic composition of the present invention may further include a transdermal penetration enhancer.
  • a transdermal penetration enhancer is a composition that allows a desired component to penetrate into blood vessel cells of the skin at a high absorption rate.
  • phospholipid components, liposome components, and the like used in lecithin cosmetics are included, but are not limited thereto.
  • an oil that can be mainly used as an oily component at least one selected from vegetable oils, mineral oils, silicone oils, and synthetic oils may be used. More specifically, mineral oil, cyclomethicone, squalane, octyldodecyl myristate, olive oil, Vitis vinifera seed oil, macadamia nut oil, glyceryl octanoate, castor oil, ethylhexyl isononanoate, dime Chicon, cyclopentasiloxane, and sunflower seed oil can be used.
  • a surfactant a higher alcohol, and the like may be added to reinforce the emulsifying ability.
  • conventional surfactants such as nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, phospholipids, etc.
  • sorbitansquinoleate polysorbate 60
  • Glyceryl stearate lipophilic glyceryl stearate
  • sorbitan oleate sorbitan stearate
  • DIA-cetylphosphate sorbitan stearate/sucrosecoate
  • glyceryl stearate/polyethylene glycol-100 Stearate ceteareth-6 olivate
  • arachidyl alcohol/behenyl alcohol/arachidyl glucoside polypropylene glycol-26-butes-26/polyethylene glycol-40 hydrogenated castor oil, etc.
  • an alcohol having 12 to 20 carbon atoms such as cetyl alcohol, stearyl alcohol, octyldodecanol, isostearyl alcohol, and the like may be used alone or in combination of one or more.
  • the aqueous phase component may further add 0.001 to 5% by weight of one or more thickeners such as carbomer, xanthan gum, bentonite, magnesium aluminum silicate, cellulose gum, dextrin palmitate, etc. to adjust the viscosity or hardness of the aqueous phase.
  • thickeners such as carbomer, xanthan gum, bentonite, magnesium aluminum silicate, cellulose gum, dextrin palmitate, etc.
  • the cosmetic composition of the present invention includes medicinal ingredients such as higher fatty acids and vitamins, sunscreen, and antioxidants (butylhydroxyanisole, propyl gallic acid, lysorbic acid, tocopheryl acetate, butylated hydroxy) as needed.
  • medicinal ingredients such as higher fatty acids and vitamins, sunscreen, and antioxidants (butylhydroxyanisole, propyl gallic acid, lysorbic acid, tocopheryl acetate, butylated hydroxy) as needed.
  • preservatives methylparaben, butylparaben, propylparaben, phenoxyethanol, imidazolidinylurea, chlorphenesin, etc.
  • colorants pH adjusters (triethanolamine, citric acid, citric acid, sodium citrate, malic acid, etc.) Sodium Malate, Pmalic Acid, Sodium Fmalate, Succinic Acid, Sodium Succinate, Sodium Hydroxide, Sodium Monohydrogen Phosphate, etc.), Moisturizing Agents (Glycerin, Sorbitol, Propylene Glycol, Butylene Glycol, Hexylene Glycol, Diglycerin , Betaine, glyceres-26, methylgluces-20, etc.), lubricants and the like can be added.
  • the cosmetic composition of the present invention further includes a substance capable of auxiliaryly providing essential nutrients to the skin, preferably, it may contain a natural scent, a cosmetic scent, or an auxiliary agent including, but not limited to, herbal medicines. have.
  • the effective content of carbon or a cosmetically acceptable salt thereof in the cosmetic composition of the present invention is not particularly limited, and may be included in an amount of 0.0001 to 20% by weight based on the total weight of the composition. Less than 0.0001% by weight of carbon or a salt thereof in the cosmetic may not have an expected improvement effect due to its small dose, and more than 20% by weight of carbon or a salt thereof may exhibit known toxicity.
  • fragment composition of the present invention may be formulated as a base for skin external use such as perfume, cosmetics, and bath, or food, pharmaceuticals, etc., and the blending amount is appropriately selected in order to achieve the desired effect according to conventional techniques in the art. Can be blended.
  • the formulation of the perfume composition of the present invention is not particularly limited, but may be any one selected from powder, granule, liquid spray, solid and gel type formulations.
  • the perfume composition includes cosmetic products including perfume, soap cleaning products including bath soap, indoor cleaning products including glass cleaners, fragrance products including car air fresheners, bath products including herbal bath products, and stationery It can be used to manufacture a fragrance product, an environmental product including an office fragrance, or an industrial product including a synthetic resin.
  • the perfume composition of the present invention contains the active ingredient, carbon, based on the total weight of the perfume composition, from 0.00001% to 10% by weight, preferably from 0.00001% by weight, depending on the product type in which the perfume composition of the present invention is embodied. It may contain 1.0% by weight, more preferably in the range of 0.00001% by weight to 0.5% by weight.
  • fragrance composition examples include soap, cosmetics, bath agents, aroma oils, etc., specifically body lotion, shampoo, hair rinse, hair conditioner, hair treatment, antiperspirant, skin lotion, skin cream, deodorant , Perfume (spray or fumigant), lipstick, lip cream, bath agent, etc., but are not limited thereto.
  • These products may contain various additives such as blood circulation accelerators, anti-inflammatory agents, moisturizing agents, astringents, inorganic salts, organic salts, oily ingredients, surfactants, herbal medicines, colors, fragrances, sulfur, sinter deposits, disinfectants, etc. .
  • the perfume composition of the present invention will generally be used as an external application for the skin of cosmetic formulations such as makeup products, skin lotions, and skin creams.
  • cosmetic formulations such as makeup products, skin lotions, and skin creams.
  • it may contain ingredients commonly used in these cosmetic formulations.
  • the perfume composition of the present invention is preferably used by being incorporated into a bathing agent in that the active ingredient, carbon, has atopic dermatitis improving activity.
  • the active ingredient may preferably be included in the range of 0.00001 to 1% by weight, more preferably 0.0001 to 0.1% by weight, based on the total weight of the bath agent.
  • the bathing agent may be added to the bath water in a concentration of 0.015 to 15 ppm and used.
  • the bath agent may contain inorganic salts, organic acids, oily ingredients, etc. in addition to the active ingredients of the perfume composition of the present invention.
  • sodium chloride, sodium hydrogen carbonate, sodium carbonate, borax, sodium sulfate, sodium sulfide, sodium sesquicarbonate, sodium nitrate, sodium thiosulfate, sodium polyphosphate, sodium phosphate, calcium oxide, magnesium oxide, calcium carbonate, magnesium carbonate, potassium chloride, sulfide Potassium and the like may be exemplified, and these may be used alone or as a mixture of two or more.
  • These inorganic salts may be added to the bath agent in an amount of 5% by weight or more, preferably 10% by weight or more, based on the total weight of the bath agent.
  • organic acid succinic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid and the like can be exemplified, and these may be used alone or in a mixture of two or more. These organic acids may be added to the bath agent in the range of 0.1 to 50% by weight, based on the total weight of the bath agent.
  • oily component examples include wax, hydrocarbon, higher fatty acid, higher alcohol, ester, and silicone oil.
  • the bath agent may also contain additional ingredients commonly used in the art.
  • these components include inorganic acids such as boric acid, metasilicic acid, and silicic anhydride; Herbal powders such as fennel, ginkgo, ginger, citrus peel, valerian root, mint, ginseng, and oats; Natural pigments, such as coal tar dye, chlorophyll, riboflavin, safflower, and anthraquinone, which have been found to be harmless to the human body; Vitamins such as vitamin A, vitamin C, vitamin D, and vitamin E; Sulfur, mica powder, clay powder, loess powder, rice bran carbide, fungicides, and preservatives.
  • inorganic acids such as boric acid, metasilicic acid, and silicic anhydride
  • Herbal powders such as fennel, ginkgo, ginger, citrus peel, valerian root, mint, ginseng, and oats
  • Natural pigments such as coal tar dye,
  • bathing agents may be prepared in any form such as granules, tablets, liquids, powders, and the like.
  • quasi-drug refers to items that are less effective than medicines among items used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing diseases of humans or animals. According to this, quasi-drugs exclude items used for pharmaceutical purposes, and include products used for the treatment or prevention of diseases of humans and animals, and products that have mild or no direct action on the human body.
  • the quasi-drug composition of the present invention is used for the purpose of preventing or improving allergic diseases or atopic dermatitis, and is not particularly limited in its formulation, for example, softening lotion, nutritional lotion, massage cream, nutrition cream, pack , A mask pack, a mask sheet, a gel or a cosmetic composition having a skin adhesive type cosmetic formulation, and may be a transdermal dosage form such as a lotion, ointment, gel, cream, patch, or spray.
  • the quasi-drug composition may be arbitrarily selected and blended according to the formulation or purpose of use of other quasi-drugs.
  • the mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (inhibition or mitigation).
  • thickeners, stabilizers, solubilizers, conventional adjuvants such as vitamins, pigments and flavors, and carriers may be included.
  • the content of the carbon or salt thereof of the present invention is preferably 0.0001 to 20% by weight, respectively, based on the total weight of the quasi-drug composition. If it exceeds 20% by weight, color and stability may be deteriorated during the preparation of the composition, and if it is less than 0.0001%, the effect is negligible.
  • components other than the essential components described above may be appropriately selected and blended by a person skilled in the art without difficulty depending on the formulation or purpose of use.
  • Mast cells (rat basophilic leukemia cell line, RBL-2H3) were purchased and used from ATCC (Manassas, VA, USA).
  • DMEM Disbecco modified eagle medium
  • FBS heat-inactivated feta bovine serum
  • penicillin and streptomycin Gibco BRL, USA
  • Cells were cultured in the culture medium. Cells were cultured under conditions of 37° C. and 5% CO 2 for experiments.
  • the mast cells were suspended in DMEM containing 10% FBS and then dispensed into a 6 well plate (Corning, USA) to a cell number of 1 ⁇ 10 6 cells/ml.
  • DNP-HSA dinitrophenylated human serum albumin; 100 ng/ml
  • anti-DNP (dinitrophenyl)-IgE was treated and carboxylic (100 ⁇ M) was treated and incubated for 24 hours, and then an immune response was induced with DNP-HSA.
  • negative control cells they were treated with DMSO instead of carbon and incubated for 24 hours, and then an immune response was induced with DNP-HSA.
  • Keratinocytes human keratinocyte cell line, HaCaT
  • ATCC Manassas, VA, USA
  • Cells were cultured using a DMEM culture medium containing 10% FBS (fetal bovine serum) and antibiotics.
  • FBS fetal bovine serum
  • a 75T-flask and a 6-well plate were used as the culture vessel, and cultured in a 37°C incubator supplied with 5% CO2. The culture medium was changed every 3 to 4 days, and when cells were excessively proliferated, they were subcultured.
  • the dispensed HaCaT cells (5 ⁇ 10 5 /well) were cultured for 24 hours and washed with PBS.
  • TNF- ⁇ tumor necrosis factor- ⁇
  • IFN- ⁇ interferon gamma
  • the immune reaction was terminated by standing in an ice bath for 10 minutes, and the culture was centrifuged at 10,000 xg for 10 minutes, and the supernatant was taken. Transferred to a 96-well plate. Histamine was quantified using ENZO's histamine release assay ELISA kit, and was measured at 450 nm wavelength of Infinite M200 pro microplate reader (TECAN).
  • RT-PCR was reacted at 45°C for 30 minutes and 94°C for 5 minutes using a one-step RT-PCR PreMix kit (iNtRON Biotechnology, Korea), followed by denaturation at 94°C for 30 seconds, and 30 at 55°C. After annealing for a second, the cycle of stretching at 72°C for 1 minute was repeated 32 times, and the last extension was performed at 72°C for 5 minutes, followed by PiQ SYBR green supermix (Bio-Rad ) And CFX ConnectTM Real-Time PCR Detection System (Bio-Rad) were used to perform quantitative PCR, and the primer sequence used at this time is as shown in [Table 1].
  • the concentration of histamine in the cell culture was measured by the enzyme immunoreaction method.
  • the histamine concentration was significantly increased in control cells sensitized with anti-DNP (dinitrophenyl)-IgE and induced an immune response with DNP-HSA compared to normal mast cells.
  • the concentration of histamine was significantly reduced (FIG. 1).
  • compositions of Preparation Examples 1 to 3 were prepared according to the following composition and composition ratio using carbon having excellent preventive and therapeutic (or preventive and improving effect) effect of the allergic disease or atopic dermatitis. It was prepared according to a conventional method.
  • the above ingredients were mixed and filled in an airtight cloth to prepare a powder.
  • tablets were prepared by tableting according to a conventional tablet preparation method.
  • the capsules were prepared by filling them into gelatin capsules according to a conventional capsule preparation method.
  • the above ingredients are dissolved by adding each ingredient to purified water according to a conventional manufacturing method, added an appropriate amount of lemon flavor, adjusted to 100 mL by adding purified water, sterilized, and filled in a brown bottle to prepare a liquid formulation.
  • Vitamin A acetate 70 ⁇ g
  • Vitamin B 1 0.13 mg
  • Vitamin B 2 0.15 mg
  • Vitamin B 6 0.5 mg
  • Vitamin B 12 0.2 ⁇ g
  • composition ratio of the vitamin and mineral mixture is relatively suitable for health food, but it may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
  • Granules can be prepared, and used for preparing health food compositions according to a conventional method.
  • composition ratio is a mixture of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the demand class, the country of demand, and the purpose of use.
  • the above blending ratio is a mixture of ingredients suitable for a relatively nutrient lotion in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the above blending ratio is a mixture of ingredients suitable for a relatively soft lotion in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the above blending ratio is a mixture of ingredients suitable for a nutritional cream in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the above blending ratio is a mixture of ingredients suitable for a massage cream in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the above blending ratio is a mixture of ingredients suitable for the pack in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the above blending ratio is a mixture of ingredients suitable for a gel in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the above blending ratio is a mixture of ingredients suitable for a cosmetic composition in a preferred embodiment, but can be applied to cosmetics for various purposes including other colored cosmetics, and a drug that can be applied thinly to the human body according to its efficacy, that is, It can be used for manufacturing as an ointment, and the blending ratio can be arbitrarily modified according to regional and ethnic preferences such as the demand class, the country of demand, and the purpose of use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a composition for the prevention or treatment of allergic diseases or atopic dermatitis comprising Carvone as an active ingredient. The composition comprising Carvone of the present invention as an active ingredient has an effect of ameliorating atopic dermatitis caused by an allergic reaction, and can be used as a composition for the prevention or treatment of various allergic diseases by reducing an inflammatory reaction.

Description

카르본 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염 예방 또는 치료용 조성물Composition for the prevention or treatment of allergic diseases or atopic dermatitis comprising carbon or its salt as an active ingredient
본 출원은 2019년 8월 19일 출원된 대한민국 특허출원 제10-2019-0101054호를 우선권으로 주장하고, 상기 명세서 전체는 본 출원의 참고문헌이다. This application claims priority to Korean Patent Application No. 10-2019-0101054 filed on August 19, 2019, and the entire specification is a reference to this application.
본 발명은 카르본(Carvone) 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention or treatment of allergic diseases or atopic dermatitis, comprising carbon (Carvone) or a salt thereof as an active ingredient.
아토피란 '이상한, 비정상적인'을 뜻하는 고대그리스어 '아토피아'에서 유래되었다. 1923년 쿡(Cooke)과 코카(Coca)는 알레르기 항원에 대한 특이 면역항체 반응을 유전적으로 야기할 수 있는 경향을 '아토피'라고 처음 부르기 시작하였다. 세계적으로 꾸준히 증가하는 추세로 산업이 발달한 선진국일수록 발병률이 증가하고 있다.Atopy is derived from the ancient Greek word'atopia', which means'strange, abnormal'. In 1923, Cooke and Coca first began to refer to a tendency that could genetically trigger a specific immune antibody response to an allergen, called atopy. With a steadily increasing trend worldwide, the incidence rate is increasing in developed countries with industrial development.
아토피의 발병 원인은 아직까지 정확히 밝혀지지 않았으나 가족력, 식생활의 변화, 알레르기 항원의 침투, 피부보호막의 이상 등 한 가지 요인에 국한되지 않고 여러 인자들이 함께 작용하여 발병한다. 주로 유·소아기에 발병하며 성인기에 지속되거나 시작될 수도 있다. 아토피의 전형적인 증상은 손, 두피, 얼굴, 목, 팔꿈치 등에 나타나나 시기별로 나타나는 양상에 차이가 있다. 유아기의 증상은 피부가 거칠어지고 건조해지며 팔다리의 바깥쪽으로 피부염이 생기며, 뺨이나 이마 등에 흔히 나타나고 손으로 긁고 나면 진물이나 딱지가 앉게 된다. 소아기의 경우는 얼굴보다는 주로 팔과 다리와 목 등의 접히는 부위에 주로 나타나고 피부가 건조해진다. 사춘기 및 성인기에는 얼굴이나 손과 같은 부위의 피부가 두껍게 변하는 증상이 나타난다.The cause of the onset of atopy has not been accurately identified yet, but is not limited to one factor such as family history, changes in diet, penetration of allergens, and abnormal skin barriers. It occurs mainly in infancy and infancy, and may persist or begin in adulthood. Typical symptoms of atopy appear on the hands, scalp, face, neck, and elbows, but there are differences in the patterns that appear by period. Symptoms of infancy are rough skin and dryness, dermatitis on the outside of limbs, cheeks and foreheads, and sores or scabs sit after scratching with hands. In childhood, it mainly appears on the folds of arms, legs and neck rather than the face, and the skin becomes dry. In puberty and adulthood, symptoms of thickening of the skin on areas such as the face and hands appear.
아토피 약물 치료제로는 국소 스테로이드, 국소 면역조절제, 전신 스테로이드, 전신 면역억제제, 항히스타민제가 사용된다. 국소 스테로이드제는 아토피 증상이 중증인 경우 사용하며 세균이나 바이러스 감염을 관리하는 것으로 가장 기본적인 방법이다. 그러나 스테로이드제는 1950년에 도입되어 수 년 동안 사용되어 왔지만 사용횟수와 농도, 기간 등에 따른 피부의 안전성과 내성의 문제점으로 인해 장기간의 사용이 제한되고 있다. 또한 피부의 위축(skin, atrophy), 모세혈관 확장증(telangiectasia), 스테로이드성 여드름(steroid acne) 등의 피부 부작용뿐만 아니라 HPA(hypothalamic-pituitary-adrenal) 억제, 쿠싱증후군(Cushing's syndrome)과 같은 잠재적인 부작용을 일으킬 수 있기 때문에 사용 시 충분한 주의가 필요하다. Local steroids, local immunomodulators, systemic steroids, systemic immunosuppressants, and antihistamines are used as atopic drugs. Topical steroids are used when atopic symptoms are severe and are the most basic method to manage bacterial or viral infections. However, steroids have been introduced in 1950 and have been used for many years, but long-term use is restricted due to problems of skin safety and tolerance depending on the frequency, concentration, and duration of use. In addition, potential skin side effects such as skin, atrophy, telangiectasia, and steroid acne, as well as inhibition of hypohalamic-pituitary-adrenal (HPA), and Cushing's syndrome. Sufficient care should be taken when using it as it may cause side effects.
국소 면역조절제 타크로리무스(tacrolimus), 피메크로리무스(pimecrolimus)는 기존의 국소 스테로이드제와 달리 장기간 사용 시에도 비교적 부작용의 가능성이 작으므로 병변 재발의 예방 목적으로 장기간에 걸쳐서 사용할 수 있다고 알려져 있어 경증의 아토피 치료와 유지 요법으로 사용하기에 적절하다. 그러나 타크로리무스는 신장기능 저하, 손떨림, 탈모 등의 부작용이 나타날 수 있으며, 피메크로리무스는 여드름, 화끈거림 뿐만 아니라 피부암, 림프종과 같은 심각한 부작용도 나타날 수 있다. 스테로이드제는 급성기의 악화 시에, 국소 면역조절제는 경증의 아토피 치료와 유지 요법으로 사용하기에 적절하나 아직까지 부작용에 대한 안전성은 확보되지 않아 대체가능한 보완제품의 필요성이 절실한 실정이다.The local immunomodulators tacrolimus and pimecrolimus are known to be used over a long period of time for the purpose of preventing recurrence of lesions as they have a relatively low possibility of side effects even when used for a long time, unlike conventional topical steroids. It is suitable for use as a treatment and maintenance therapy. However, tacrolimus may have side effects such as decreased kidney function, hand tremor, and hair loss, and pimecrolimus may have serious side effects such as acne and burning as well as skin cancer and lymphoma. When steroids worsen in the acute phase, local immunomodulators are suitable for use as treatment and maintenance therapy for mild atopy, but safety against side effects has not yet been secured, so there is an urgent need for alternative supplements.
이에 본 출원인은 부작용이 적으며 아토피 피부염 증상을 완화시키는 데 효과가 있는 소재를 개발하기 위해 노력한 결과, 카르본(Carvone)이 아토피 증상을 완화하고, 염증 반응을 개선시킨다는 점을 확인함으로써 본 발명을 완성하였다.Accordingly, the applicant of the present invention has made efforts to develop a material that has few side effects and is effective in relieving atopic dermatitis symptoms, and as a result, confirming that Carvone relieves atopic symptoms and improves the inflammatory response. Completed.
선행기술문헌 Prior art literature
특허문헌 대한민국 공개특허 제10-2018-0128602호 Patent Document Korean Patent Application Publication No. 10-2018-0128602
본 발명의 목적은 카르본(Carvone) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis, comprising as an active ingredient carboxylic (Carvone) or a pharmaceutically acceptable salt thereof.
본 발명의 또 다른 목적은 카르본 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 조성물을 제공하는 것이다.Another object of the present invention is to provide a composition for the prevention or improvement of allergic diseases or atopic dermatitis comprising carbon or a salt thereof as an active ingredient.
그러나, 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problems, and other problems that are not mentioned will be clearly understood by those skilled in the art from the following description.
본 발명은 상술한 문제점을 해결하기 위한 것으로, 카르본(Carvone) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention is to solve the above-described problems, and provides a pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis, comprising as an active ingredient carboxylic (Carvone) or a pharmaceutically acceptable salt thereof.
본 발명의 일 양상에 따르면, 상기 알러지성 질환은 부종, 과민증(anaphylaxis), 알러지성 비염(allergic rhinitis), 천식(asthma), 알러지성 결막염(allergic conjunctivitis), 알러지성 피부염(allergic dermatitis),　접촉성 피부염, 두드러기, 소양증, 곤충 알러지, 식품 알러지 및 약품 알러지로 이루어진 군에서 선택될 수 있으나, 이에 한정되지 않는다.According to one aspect of the present invention, the allergic disease is edema, anaphylaxis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, 　 contact It may be selected from the group consisting of sexual dermatitis, urticaria, pruritus, insect allergy, food allergy and drug allergy, but is not limited thereto.
본 발명의 일 양상에 따르면, 상기 유효성분은 IL-4(Interleukin-4), IL-13, TNF-α(tumor necrosis factor-alpha), IL-1β, IL-6 또는 IL-8의 발현을 감소시키거나, 히스타민의 분비량을 감소시킴으로써 항알러지 효과, 아토피 피부염의 예방 또는 치료 효과를 나타낼 수 있다.According to an aspect of the present invention, the active ingredient expresses IL-4 (Interleukin-4), IL-13, TNF-α (tumor necrosis factor-alpha), IL-1β, IL-6, or IL-8. By reducing or reducing the secretion amount of histamine, it may exhibit anti-allergic effects, prevent or treat atopic dermatitis.
또한, 본 발명은 카르본 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 의약외품 조성물을 제공한다.In addition, the present invention provides a quasi-drug composition for the prevention or improvement of allergic diseases or atopic dermatitis comprising carbon or a pharmaceutically acceptable salt thereof as an active ingredient.
또한, 본 발명은 카르본 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for the prevention or improvement of allergic diseases or atopic dermatitis comprising carbon or a cosmetically acceptable salt thereof as an active ingredient.
또한, 본 발명은 카르본 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 향료 조성물을 제공한다.In addition, the present invention provides a perfume composition for the prevention or improvement of allergic diseases or atopic dermatitis, comprising carbon or a cosmetically acceptable salt thereof as an active ingredient.
또한, 본 발명은 카르본 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for the prevention or improvement of allergic diseases or atopic dermatitis, comprising as an active ingredient carbonyl or a food acceptable salt thereof.
또한, 본 발명은 카르본 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 조성물을 개체에 투여 또는 복용시키는 단계를 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 치료 방법을 제공한다.In addition, the present invention provides a method for preventing or treating allergic diseases or atopic dermatitis, comprising administering or taking a composition comprising carbon or a pharmaceutically acceptable salt thereof as an active ingredient to an individual.
또한, 본 발명은 카르본 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 조성물의 알러지성 질환 또는 아토피 피부염의 예방 또는 치료 용도를 제공한다.In addition, the present invention provides a use of a composition comprising carbon or a pharmaceutically acceptable salt thereof as an active ingredient to prevent or treat allergic diseases or atopic dermatitis.
본 발명의 카르본을 유효성분으로 포함하는 조성물은 알러지 반응으로 인한 아토피 피부염의 개선 효과가 있으며, 염증 반응을 감소시킴으로써 다양한 알러지성 질환의 예방 또는 치료용(개선용) 조성물로 사용될 수 있다.The composition comprising the carboxylic acid of the present invention as an active ingredient has an effect of improving atopic dermatitis due to an allergic reaction, and can be used as a composition for preventing or treating (improving) various allergic diseases by reducing the inflammatory response.
도 1은 카르본(Carvone)을 처리한 비만세포(RBL-2H3 세포)에서의 히스타민의 분비량 변화를 나타내는 그래프이다(각 값은 3 개의 독립적 웰로부터 수득한 3 회의 평균 ± SEM 임; 막대 위의 글자는 P<0.05에서 통계적 유의적 차이를 나타낸 것임).1 is a graph showing the change in the secretion amount of histamine in mast cells (RBL-2H3 cells) treated with Carvone (each value is the mean ± SEM of three times obtained from three independent wells; on a bar) Letters show a statistically significant difference at P<0.05).
도 2는 카르본(Carvone)을 처리한 비만세포에서 염증성 사이토카인 관련 분자들(IL-4, IL-13 및 TNF-α)의 발현변화를 나타내는 그래프이다(각 값은 3 개의 독립적 웰로부터 수득한 3 회의 평균 ± SEM 임; 막대 위의 글자는 P<0.05에서 통계적 유의적 차이를 나타낸 것임).2 is a graph showing changes in the expression of inflammatory cytokine-related molecules (IL-4, IL-13 and TNF-α) in mast cells treated with Carvone (each value is obtained from three independent wells. Mean ± SEM of one trip; the letters on the bars represent statistically significant differences at P<0.05).
도 3은 카르본(Carvone)을 처리한 각질형성세포에서 염증성 사이토카인 관련 분자들(IL-1β, IL-6 및 IL-8)의 발현변화를 나타내는 그래프이다(각 값은 3 개의 독립적 웰로부터 수득한 3 회의 평균 ± SEM 임; 막대 위의 글자는 P<0.05에서 통계적 유의적 차이를 나타낸 것임).3 is a graph showing changes in the expression of inflammatory cytokine-related molecules (IL-1β, IL-6 and IL-8) in keratinocytes treated with Carvone (each value is from 3 independent wells. Means of 3 obtained ± SEM; letters on the bars show statistically significant differences at P<0.05).
본 발명자들은 카르본이 아토피 증상을 완화시키며, 세포의 면역반응으로 인해 분비되는 염증성 사이토카인인 IL-4, IL-13, TNF-α, IL-1β, IL-6 또는 IL-8의 발현을 유의적으로 감소시키는 것과 히스타민의 분비량을 감소시키는 것을 확인함으로써, 본 발명을 완성하였다.The present inventors found that carbon relieves atopic symptoms and expresses IL-4, IL-13, TNF-α, IL-1β, IL-6, or IL-8, which are inflammatory cytokines secreted due to the immune response of cells. By confirming that the amount of secretion of histamine was significantly reduced and the amount of histamine was decreased, the present invention was completed.
이하, 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 카르본(Carvone) 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 치료용(개선용) 조성물을 제공한다.The present invention provides a composition for preventing or treating (improving) allergic diseases or atopic dermatitis, comprising carbon (Carvone) or a salt thereof as an active ingredient.
구체적으로 상기 카르본(Carvone)은 테르페노이드(Terpenoid)계 화합물로서, IUPAC 명(name)은 2-메틸-5-(프로프-1-엔-2-일)사이클로헥스-2-엔-1온(2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one)이다. 카르본의 화학식은 C10H14O이고 분자량은 150.2 g/mol이며, 구조는 하기 [화학식 1](카르본(carvone)의 분자 구조)과 같다. 카르본은 무색 또는 담황색의 투명한 액체이며 물, 알코올, 클로로포름 에테르 등에서는 녹으나 글리세롤에서는 녹지 않는다. 다양한 에센셜 오일에서 발견되는 것으로 알려져 있고, 캐러웨이(caraway)(Carum carvi)의 씨앗에 풍부하게 존재한다. 카르본은 식용 가능한 안전한 물질로 알려져 있으며, EFSA(European Food Safety Athority), JECFA(Joint FAO/WHO Expert Committee on Food Additives)에 의해 향미료(flavor agents) 성분으로 승인되어 있고, 산업적으로 맛과 향을 내기 위한 목적으로 이용되어져 왔다.Specifically, the carvone is a terpenoid-based compound, and the IUPAC name is 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-ene- 1-one (2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one). The chemical formula of carbon is C 10 H 14 O, the molecular weight is 150.2 g/mol, and the structure is as shown in [Chemical Formula 1] (molecular structure of carvone). Carbon is a colorless or pale yellow transparent liquid and is soluble in water, alcohol, chloroform ether, etc., but not in glycerol. It is known to be found in a variety of essential oils, and is abundantly present in the seeds of caraway (Carum carvi). Carbon is known to be a safe edible substance, and has been approved as a flavor agent by EFSA (European Food Safety Athority) and JECFA (Joint FAO/WHO Expert Committee on Food Additives), and industrially has taste and aroma. It has been used for betting purposes.
[화학식 1][Formula 1]
Figure PCTKR2020010976-appb-I000001
Figure PCTKR2020010976-appb-I000001
본 발명의 카르본은 상기 카르본과 동일한 효능을 갖는 범위 내에서 카르본 수화물, 카르본 유도체 등을 포함할 수 있고, 이의 용매 화합물이나 입체 이성질체 또한 포함할 수 있다.The carbon of the present invention may include a carboxylic hydrate, a carboxylic derivative, and the like within a range having the same efficacy as the carbon, and may also include a solvate or stereoisomer thereof.
상기 카르본의 수득방법은 특별히 한정되지 않으며, 상기 카르본을 함유하고 있는 식물로부터 분리하거나, 공지된 제법을 사용하여 화학적으로 합성하거나, 시판되는 것을 사용할 수 있다. 상기 카르본은 d-카르본(d-Carvone, 하기 화학식 2)일 수 있다.The method for obtaining the carbon is not particularly limited, and may be isolated from a plant containing the carbon, chemically synthesized using a known manufacturing method, or a commercially available one may be used. The carbon may be d-carvone (d-Carvone, Formula 2 below).
[화학식 2][Formula 2]
Figure PCTKR2020010976-appb-I000002
Figure PCTKR2020010976-appb-I000002
본 발명에서, 용어 "화장품학적으로 허용 가능한 염", "식품학적으로 허용 가능한 염", "약학적으로 허용 가능한 염" 또는 "이의 염"은 유리산(free acid)에 의해 형성된 산 부가염일 수 있다. 산 부가염은 통상의 방법, 예를 들어 화합물을 과량의 산 수용액에 용해시키고, 이 염을 수혼화성 유기 용매, 예를 들어 메탄올, 에탄올, 아세톤 또는 아세토니트릴을 사용하여 침전시켜서 제조할 수 있다. 또한, 동 몰량의 화합물 및 물 중의 산 또는 알코올(예를 들어, 글리콜 모노메틸 에테르)을 가열하고, 이어서 상기 혼합물을 증발시켜 건조시키거나, 또는 석출된 염을 흡인 여과시킬 수 있다.In the present invention, the term “cosmetically acceptable salt”, “food pharmaceutically acceptable salt”, “pharmaceutically acceptable salt” or “salt thereof” may be an acid addition salt formed by a free acid. have. The acid addition salt can be prepared by a conventional method, for example, dissolving the compound in an excess aqueous acid solution, and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. In addition, the same molar amount of the compound and an acid or alcohol (eg, glycol monomethyl ether) in water may be heated, and then the mixture may be evaporated to dryness, or the precipitated salt may be suction filtered.
상기 유리산으로는 무기산 또는 유기산을 사용할 수 있다. 상기 무기산의 비제한적인 예로는 염산, 인산, 황산, 질산, 주석산 등을 사용할 수 있으며, 이들은 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다. 상기 유기산의 비제한적인 예로는 메탄술폰산, p-톨루엔술폰산, 아세트산, 트리플루오로아세트산, 말레인산(maleic acid), 숙신산, 옥살산, 벤조산, 타르타르산, 푸마르산 (fumaric acid), 만데르산, 프로피온산(propionic acid), 구연산(citric acid), 젖산(lactic acid), 글리콜산(glycollic acid), 글루콘산(gluconic acid), 갈락투론산(galacturonic acid), 글루탐산, 글루타르산(glutaric acid), 글루쿠론산 (glucuronic acid), 아스파르트산, 아스코르브산, 카본산, 바닐릭산, 하이드로아이오딕산 등을 사용할 수 있다. 이들은 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.As the free acid, an inorganic acid or an organic acid may be used. Non-limiting examples of the inorganic acid may be hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, and the like, which may be used alone or in combination of two or more. Non-limiting examples of the organic acid include methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid (propionic acid). acid), citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid (glucuronic acid), aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, and the like can be used. These may be used alone or in combination of two or more.
또한, 상기 카르본은 염기를 사용하여 화장품학적으로 또는 식품학적으로 허용 가능한 금속염을 만들 수 있다. 알칼리 금속 또는 알칼리 토금속 염은, 예를 들어 화합물을 과량의 알칼리 금속 수산화물 또는 알칼리 토금속 수산화물 용액 중에 용해시키고, 비용해 화합물 염을 여과한 후 여액을 증발, 건조시켜 얻을 수 있다. 상기 금속염으로는 특히 나트륨, 칼륨 또는 칼슘염을 제조하는 것이 바람직하나 이들에 제한되는 것은 아니다. 또한, 이에 대응하는 은염은 알칼리 금속 또는 알칼리 토금속 염을 적당한 은염 (예를 들어, 질산은)과 반응시켜 얻을 수 있다.In addition, the carbon can be made cosmetically or food acceptable metal salt using a base. The alkali metal or alkaline earth metal salt can be obtained, for example, by dissolving the compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate. As the metal salt, it is particularly preferable to prepare a sodium, potassium or calcium salt, but is not limited thereto. Further, the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (eg, silver nitrate).
상기 카르본의 염은, 달리 지시되지 않는 한, 상기 카르본의 화합물에 존재할 수 있는 산성 또는 염기성 기의 염을 모두 포함할 수 있다. 예를 들어 상기 카르본의 염으로는 하이드록시기의 나트륨, 칼슘 및 칼륨염 등이 포함될 수 있고, 아미노기의 기타 화장품학적으로 허용 가능한 염으로는 하드로브로마이드, 황산, 수소 황산염, 인산염, 수소 인산염, 이수소 인산염, 아세테이트, 숙시네이트, 시트레이트, 타르트레이트, 락테이트, 만델레이트, 메탄술포네이트 (메실레이트) 및 p-톨루엔술포네이트 (토실레이트)염 등을 들 수 있으며 당업계에서 알려진 염의 제조 방법을 통하여 제조될 수 있다.The salt of the carboxylic, unless otherwise indicated, may include all salts of acidic or basic groups that may be present in the compound of the carboxylic. For example, the salt of the carboxylic acid may include sodium, calcium and potassium salts of the hydroxy group, and other cosmetically acceptable salts of the amino group include hard bromide, sulfuric acid, hydrogen sulfate, phosphate, hydrogen phosphate , Dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts, and the like, and salts known in the art It can be manufactured through a manufacturing method.
본 발명에서 "알러지성 질환"이란 외부 항원에 대한 신체 내 면역 반응이 과도하게 나타나는 알러지(allergy) 반응에 의해 발병하는 질환을 의미하는 것으로서, 구체적으로 부종, 과민증(anaphylaxis), 알러지성 비염(allergic rhinitis), 천식(asthma), 알러지성 결막염(allergic conjunctivitis), 알러지성 피부염(allergic dermatitis),　접촉성 피부염, 두드러기, 소양증, 곤충 알러지, 식품 알러지 및 약품 알러지로 이루어진 군에서 선택되는 하나 이상의 질환일 수 있으나, 이에 한정되지 않는다.In the present invention, "allergic disease" refers to a disease caused by an allergy reaction in which the body's immune response to an external antigen is excessive, and specifically, edema, hypersensitivity (anaphylaxis), allergic rhinitis (allergic) rhinitis), asthma, allergic conjunctivitis, allergic dermatitis, contact dermatitis, urticaria, pruritus, insect allergy, food allergy, and drug allergy. However, it is not limited thereto.
본 발명에서 "아토피 피부염"은 알러지성 질환 중의 하나로서 가려움증, 피부 건조, 피부 두께 증가, 특징적인 습진과 같은 증상을 동반하는 피부 질환이다. In the present invention, "atopic dermatitis" is one of allergic diseases and is a skin disease accompanied by symptoms such as itching, dry skin, increased skin thickness, and characteristic eczema.
본 발명에 따른 알러지성 질환 또는 아토피 피부염의 예방 또는 치료용 약학적 조성물은 카르본 또는 이의 약학적으로 허용 가능한 염을 포함하는 것이라면 그 함량을 특별히 제한하지는 않으나, 바람직하게 상기 카르본의 용량은 0.1 μM 내지 1000 μM의 농도로 포함할 수 있으나, 이에 한정되지 않는다. 이때, 카르본이 상기 농도 범위 미만인 경우, 바람직한 예방 또는 치료 효과를 발휘하기 어려운 문제점이 있고, 카르본이 상기 농도 범위를 초과하는 경우, 세포독성을 포함한 독성의 우려사항이 있을 수 있다.The pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis according to the present invention is not particularly limited in its content as long as it contains carbonyl or a pharmaceutically acceptable salt thereof, but preferably the dose of carboxylic is 0.1 It may be included in a concentration of μM to 1000 μM, but is not limited thereto. At this time, if the carbon is less than the above concentration range, there is a problem that it is difficult to exert a desirable preventive or therapeutic effect, and if the carbon exceeds the above concentration range, there may be concerns of toxicity including cytotoxicity.
본 발명에 따른 알러지성 질환 또는 아토피 피부염의 예방 또는 치료용 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구제 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화되어 사용할 수 있고, 제형화를 위하여 약학 조성물의 제조에 통상적으로 사용되는 적절한 담체, 부형제 또는 희석제를 포함할 수 있다.The pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis according to the present invention, according to a conventional method, respectively, oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and It may be formulated and used in the form of a sterile injectable solution, and may include a suitable carrier, excipient, or diluent commonly used in the preparation of pharmaceutical compositions for formulation.
상기 담체 또는, 부형제 또는 희석제로는 락토즈, 덱스트로즈, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리게이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한 다양한 화합물 혹은 혼합물을 들 수 있다.As the carrier or excipient or diluent, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, undecided And various compounds or mixtures including vaginal cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
제제화할 경우에는 보통 사용하는 충진제, 중량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 제조할 수 있다.In the case of formulation, it can be prepared using diluents or excipients such as fillers, weight agents, binders, wetting agents, disintegrants, and surfactants that are usually used.
경구 투여를 위한 고형제제는 상기 카르본에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘보네이트, 수크로스 또는 락토오스, 젤라틴 등을 섞어 제조할 수 있다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용할 수 있다.Solid preparations for oral administration may be prepared by mixing the carbon with at least one excipient, such as starch, calcium bonate, sucrose or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc can also be used.
경구를 위한 액상 제제로는 현탁액, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용하는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등을 포함할 수 있다.Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. may be included. .
비경구 투여를 위한 제제에는 멸균된 수용액, 비수용성제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등을 사용할 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세롤젤라틴 등을 사용할 수 있다.Formulations for parenteral administration include sterile aqueous solutions, non-aqueous agents, suspensions, emulsions, lyophilized formulations, and suppositories. As the non-aqueous solvent and suspension, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerol gelatin, and the like can be used.
본 발명에 따른 알러지성 질환 또는 아토피 피부염의 예방 또는 치료용 약학 조성물의 바람직한 투여량은 환자의 상태, 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서는 1일 0.0001 내지 2,000 mg/kg으로, 바람직하게는 0.001 내지 2,000 mg/kg으로 투여할 수 있다. 투여는 하루에 한 번 투여할 수도 있고, 수회 나누어서 투여할 수도 있다. 다만, 상기 투여량에 의해서 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis according to the present invention varies depending on the patient's condition, weight, degree of disease, drug form, route and duration of administration, but may be appropriately selected by those skilled in the art. I can. However, for a desirable effect, it may be administered at 0.0001 to 2,000 mg/kg per day, preferably 0.001 to 2,000 mg/kg. Administration may be administered once a day, or may be divided several times. However, the scope of the present invention is not limited by the dosage.
본 발명에 따른 알러지성 질환 또는 아토피 피부염의 예방 또는 치료용 약학 조성물은 쥐, 생쥐, 가축, 인간 등의 포유 동물에 다양한 경로로 투여할 수 있다. 투여의 모든 방식은 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관내(intracerebroventricular) 주사에 의해서 투여할 수 있다.The pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis according to the present invention can be administered to mammals such as mice, mice, livestock, and humans by various routes. All modes of administration can be administered by, for example, oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
본 발명에 따른 유효성분을 포함하는 조성물은 면역 반응으로 인해 과도하게 분비되는 IL-4, IL-13, TNF-α, IL-1β, IL-6 또는 IL-8의 발현을 감소시키거나 히스타민의 분비량을 감소시킴으로써 알러지 질환 또는 아토피 피부염 증상을 개선하고 예방할 수 있다.The composition comprising the active ingredient according to the present invention reduces the expression of IL-4, IL-13, TNF-α, IL-1β, IL-6, or IL-8 that is excessively secreted due to an immune response, or By reducing the amount of secretion, allergic diseases or atopic dermatitis symptoms can be improved and prevented.
대표적인 가려움증 매개체인 히스타민은 1927년 Lewis에 의해서 염증성 피부질환에서 가려움증을 일으킨다고 제안되었다. 피부의 히스타민의 주요 공급원은 비만세포로 합성 및 저장된 히스타민이 자극에 반응하여 분비된다. 분비된 히스타민은 각질 세포에 존재하는 히스타민 수용체를 통하여 가려움증 외에도 혈관에 대한 직접적인 작용과 감각 신경에서 신경펩티드(neuropeptide)의 방출로 인해 홍반, 통증, 혈관 확장 및 부종을 유발한다.Histamine, a representative itching mediator, was proposed by Lewis in 1927 to cause itching in inflammatory skin diseases. The main source of histamine in the skin is mast cells, and histamine, which is synthesized and stored, is secreted in response to stimulation. The secreted histamine causes erythema, pain, vasodilation and swelling due to direct action on blood vessels and release of neuropeptide from sensory nerves in addition to itching through histamine receptors present in keratinocytes.
본 발명의 일 실시예에서는, 카르본 처리 결과, 대표적인 가려움증 매개체인 히스타민의 분비량이 현저히 감소되는 것을 확인함으로써 카르본이 알러지 질환 또는 아토피 피부염 증상을 개선하고 예방할 수 있음을 확인하였다(도 1).In one embodiment of the present invention, by confirming that the secretion of histamine, a representative itching mediator, is significantly reduced as a result of carbon treatment, it was confirmed that carbon can improve and prevent symptoms of allergic disease or atopic dermatitis (FIG. 1).
또한, 본 발명의 일 실시예에서는, 카르본 처리 결과, 세포의 면역반응으로 분비되는 염증성 사이토카인인 IL-4, IL-13, TNF-α, IL-1β, IL-6 및 IL-8의 발현이 현저히 감소한 것을 확인함으로써 카르본이 과도한 면역 반응을 억제하고 염증을 치료할 수 있음을 할 수 있었다(도 2, 도 3).In addition, in one embodiment of the present invention, as a result of carbon treatment, the inflammatory cytokines IL-4, IL-13, TNF-α, IL-1β, IL-6 and IL-8 secreted by the immune response of cells By confirming that the expression was significantly reduced, it was possible that carbon could suppress an excessive immune response and treat inflammation (FIG. 2, FIG. 3).
또한, 본 발명은 카르본(Carvone) 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 조성물을 제공한다.In addition, the present invention provides a composition for preventing or improving allergic diseases or atopic dermatitis, including carvone or a salt thereof as an active ingredient.
상기 카르본의 구체적인 내용은 전술한 바와 같다.The specific content of the carbon is as described above.
본 발명의 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 조성물은 건강기능식품 조성물, 화장료 조성물, 향료 조성물 또는 의약외품 조성물일 수 있다.The composition for preventing or improving allergic diseases or atopic dermatitis of the present invention may be a health functional food composition, a cosmetic composition, a perfume composition, or a quasi-drug composition.
본 발명에서 용어 "건강기능식품"은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 '기능성'이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당 업계에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조시에는 당 업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 건강기능식품 조성물은 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 항알러지 효과 또는 아토피 피부염 증상 완화 효과를 증진시키기 위한 보조제로 섭취가 가능하다.In the present invention, the term "health functional food" refers to a food manufactured and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functions for the human body. Here, "functionality" means obtaining useful effects for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body. The health functional food of the present invention can be prepared by a method commonly used in the art, and at the time of manufacture, it can be prepared by adding raw materials and ingredients commonly added in the art. In addition, the formulation of the health functional food may be prepared without limitation as long as it is a formulation recognized as a health functional food. The health functional food composition of the present invention has the advantage of not having side effects that may occur when taking the drug for a long period of time, unlike general drugs, using food as a raw material, and is excellent in portability, enhancing the anti-allergic effect or the relief effect of atopic dermatitis symptoms. It can be ingested as a supplement to make.
본 발명에 따른 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 건강기능식품에 있어서, 상기 카르본을 건강기능식품의 첨가물로 사용하는 경우 이를 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합양은 예방, 건강 또는 치료 등의 각 사용 목적에 따라 적합하게 결정할 수 있다.In the health functional food for the prevention or improvement of allergic diseases or atopic dermatitis according to the present invention, when the carbon is used as an additive of a health functional food, it can be added as it is or used with other foods or food ingredients, and is usually It can be used appropriately according to the method of phosphorus. The mixing amount of the active ingredient can be appropriately determined according to each purpose of use, such as prevention, health or treatment.
건강기능식품의 제형은 산제, 과립제, 환, 정제, 캡슐제의 형태뿐만 아니라 일반 식품 또는 음료의 형태 어느 것이나 가능하다.Formulations of health functional foods may be in the form of powders, granules, pills, tablets, capsules, as well as general foods or beverages.
상기 식품의 종류에는 특별히 제한은 없고, 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸콜렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 식품을 모두 포함할 수 있다.The type of food is not particularly limited, and examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, and dairy products including ice cream. , Various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes, and may include all foods in the usual sense.
일반적으로, 식품 또는 음료의 제조시에 상기 카르본은 원료 100 중량부에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가할 수 있다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 또한 본 발명은 천연물로부터의 분획물을 이용하는 점에서 안전성 면에서 문제가 없으므로 상기 범위 이상의 양으로도 사용할 수 있다.In general, when preparing food or beverage, the carbon may be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on 100 parts by weight of the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the amount may be less than the above range, and the present invention has no problem in terms of safety in terms of using fractions from natural products. It can also be used in the above amount.
본 발명에 따른 기능성식품 중 음료는 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 수크로스와 같은 디사카라이드 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜일 수 있다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명에 따른 음료 100 mL당 약 0.01 ~ 0.04 g, 바람직하게는 약 0.02 ~ 0.03 g일 수 있다.Among the functional foods according to the present invention, the beverage may contain various flavoring agents or natural carbohydrates as an additional component, like a conventional beverage. The natural carbohydrates described above may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used. The ratio of the natural carbohydrate may be about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the beverage according to the present invention.
상기 외에 본 발명에 따른 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 건강기능식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제를 함유할 수 있다. 그 밖에 본 발명의 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 건강기능식품 조성물은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 제한되지 않으나 본 발명의 기능성식품 100 중량부 대비 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the health functional food for the prevention or improvement of allergic diseases or atopic dermatitis according to the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloids. It may contain thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages. In addition, the health functional food composition for preventing or improving allergic diseases or atopic dermatitis of the present invention may contain flesh for the manufacture of natural fruit juice, fruit juice drink, and vegetable drink. These ingredients may be used independently or in combination. The ratio of these additives is not limited, but it is generally selected from 0.01 to 0.1 parts by weight based on 100 parts by weight of the functional food of the present invention.
본 발명에서 사용되는 용어, "화장료 조성물"은 상기 화합물을 포함하는 조성물로서 그 제형은 어떠한 형태라도 가능하다. 이러한 제형의 예를 들면 상기 조성물을 이용하여 제조된 화장료는 영양크림, 아이크림, 마사지크림, 클렌징 크림과 같은 크림류, 팩류, 영양로션과 같은 로션류, 에센스류, 유연화장수, 영양화장수와 같은 화장수류, 파우더류, 파운데이션류 및 메이크업 베이스류 등이고, 본 발명의 목적을 달성하기 위하여 이러한 제형 중 어떠한 형태로도 제조되어 상용화될 수 있으며, 상기 예들에 한정되지 않는다. 또한, 본 발명에 따른 화장료 조성물에는 통상의 화장료 제조 방법으로 제형화할 수 있다. 구체적으로 본 발명의 화장료는 스킨로션, 스킨 소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스처 로션, 영양로션, 맛사지 크림, 영양크림, 모이스처 크림, 핸드크림, 에센스, 팩, 마스크팩, 마스크시트, 비누, 샴푸, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션, 바디클렌저, 유액, 프레스파우더, 루스파우더 및 아이섀도로 구성된 그룹에서 선택된 어느 하나의 제형을 가지는 것일 수 있다.The term "cosmetic composition" used in the present invention is a composition including the compound, and the formulation may be in any form. For example, cosmetic products prepared using the above composition include creams such as nutritional cream, eye cream, massage cream, cleansing cream, packs, lotions such as nutritional lotion, essences, softening lotion, lotion such as nutritional lotion. Types, powders, foundations, makeup bases, and the like, and can be manufactured and commercialized in any of these formulations to achieve the object of the present invention, and are not limited to the above examples. In addition, the cosmetic composition according to the present invention can be formulated by a conventional cosmetic preparation method. Specifically, the cosmetics of the present invention are skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, pack, mask pack, mask sheet , Soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, press powder, loose powder, and eye shadow.It may have any one formulation selected from the group consisting of.
본 발명의 화장료 조성물은 카르본 또는 이의 염에 더하여 부형제, 담체 등 기타 첨가제를 포함할 수 있으며, 일반 피부 화장료에 배합되는 보통의 성분을 필요한 만큼 적용 배합하는 것이 가능하다.The cosmetic composition of the present invention may contain other additives such as excipients, carriers, etc. in addition to carbon or salts thereof, and it is possible to apply and mix ordinary ingredients to be blended in general skin cosmetics as needed.
구체적으로, 본 발명의 화장료 조성물은 경피 침투 강화제를 추가로 포함할 수 있다. 본 발명에서 사용되는 용어, 경피 침투 강화제란 피부의 혈관세포 내로 원하는 성분이 높은 흡수율로 침투할 수 있게 해주는 조성물이다. 바람직하게는 레시틴 화장품에 사용되는 다른 인지질 성분, 리포좀 성분 등이 포함되지만 이에 국한되지는 않는다.Specifically, the cosmetic composition of the present invention may further include a transdermal penetration enhancer. The term used in the present invention, a transdermal penetration enhancer, is a composition that allows a desired component to penetrate into blood vessel cells of the skin at a high absorption rate. Preferably, other phospholipid components, liposome components, and the like used in lecithin cosmetics are included, but are not limited thereto.
또한, 유상 성분으로서 주로 사용될 수 있는 오일로는 식물성 오일, 광물성 오일, 실리콘유 및 합성유 중에서 선택된 하나 이상을 사용할 수 있다. 보다 구체적으로, 미네랄오일, 사이크로메치콘, 스쿠알란, 옥틸도데실 미리스테이트, 올리브오일, 비티스 비니페라 씨드 오일, 마카다미아너트오일, 글리세릴옥타노에이트, 캐스터오일, 에칠헥실 이소노나노에이트, 디메치콘, 사이크로펜타실록산 및 선플라워씨드 오일 등을 사용할 수 있다.In addition, as an oil that can be mainly used as an oily component, at least one selected from vegetable oils, mineral oils, silicone oils, and synthetic oils may be used. More specifically, mineral oil, cyclomethicone, squalane, octyldodecyl myristate, olive oil, Vitis vinifera seed oil, macadamia nut oil, glyceryl octanoate, castor oil, ethylhexyl isononanoate, dime Chicon, cyclopentasiloxane, and sunflower seed oil can be used.
또한, 유화 능력을 보강하기 위하여 계면활성제, 고급 알콜 등을 0.1 내지 5 중량% 첨가할 수 있다. 이러한 계면 활성제로는 비이온 계면활성제, 음이온성 계면 활성제, 양이온성 계면 활성제, 양성 계면 활성제, 인지질 등과 같은 통상적인 계면활성제를 사용할 수 있으며, 구체적으로, 소르비탄세스퀴놀리에이트, 폴리솔베이트 60, 글리세릴 스테아레이트, 친유형 글리세릴스테아레이트, 소르비탄올리에이트, 소르비탄 스테아레이트, 디이에이-세틸포스페이트, 소르비탄스테아레이트/수크로스코코에이트, 글리세릴스테아레이트/폴리에틸렌글라이콜-100 스테아레이트, 세테아레스-6 올리베이트, 아라키딜알코올/베헤닐알코올/아라키딜 글루코사이드, 폴리프로필렌글라이콜-26-부테스-26/폴리에틸렌글라이콜-40 하이드로제네이티드 캐스터오일 등을 사용할 수 있다. 고급 알콜로는 탄소수가 12 내지 20인 알코올, 예컨대 세틸알코올, 스테아릴 알코올, 옥틸도데칸올, 이소스테아릴 알코올 등을 단독으로 또는 1종 이상 혼합하여 사용할 수 있다.In addition, 0.1 to 5% by weight of a surfactant, a higher alcohol, and the like may be added to reinforce the emulsifying ability. As such surfactants, conventional surfactants such as nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, phospholipids, etc. may be used, and specifically, sorbitansquinoleate, polysorbate 60 , Glyceryl stearate, lipophilic glyceryl stearate, sorbitan oleate, sorbitan stearate, DIA-cetylphosphate, sorbitan stearate/sucrosecoate, glyceryl stearate/polyethylene glycol-100 Stearate, ceteareth-6 olivate, arachidyl alcohol/behenyl alcohol/arachidyl glucoside, polypropylene glycol-26-butes-26/polyethylene glycol-40 hydrogenated castor oil, etc. can be used. have. As the higher alcohol, an alcohol having 12 to 20 carbon atoms, such as cetyl alcohol, stearyl alcohol, octyldodecanol, isostearyl alcohol, and the like may be used alone or in combination of one or more.
수상 성분은 수상의 점도 또는 경도를 조절하기 위하여 카보머, 잔탄검, 벤토나이트, 마그네슘알루미늄실리케이트, 셀룰로오스검, 덱스트린 팔미테이트 등과 같은 1종 이상의 점증제를 0.001 내지 5 중량% 더 첨가할 수 있다.The aqueous phase component may further add 0.001 to 5% by weight of one or more thickeners such as carbomer, xanthan gum, bentonite, magnesium aluminum silicate, cellulose gum, dextrin palmitate, etc. to adjust the viscosity or hardness of the aqueous phase.
또한, 본 발명의 화장료 조성물에는 필요에 따라 고급 지방산, 비타민 등의 약효 성분과 자외선 차단제, 산화 방지제(부틸히드록시아니솔, 갈릭산프로필, 엘리소르빈산, 토코페릴아세테이드, 부틸레이티드하이드록시톨루엔 등), 방부제(메칠파라벤, 부틸파라벤, 프로필파라벤, 페녹시에탄올, 이미다졸리디닐우레아, 클로르페네신 등), 착색제, pH 조절제(트리에탄올아민, 씨트릭애씨드, 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등), 보습제(글리세린, 솔비톨, 프로필렌 글라이콜, 부틸렌 글라이콜, 헥실렌 글라이콜, 디글리세린, 베타인, 글리세레스-26, 메칠글루세스-20 등), 윤활제 등의 성분을 더 첨가할 수 있다.In addition, the cosmetic composition of the present invention includes medicinal ingredients such as higher fatty acids and vitamins, sunscreen, and antioxidants (butylhydroxyanisole, propyl gallic acid, lysorbic acid, tocopheryl acetate, butylated hydroxy) as needed. Toluene), preservatives (methylparaben, butylparaben, propylparaben, phenoxyethanol, imidazolidinylurea, chlorphenesin, etc.), colorants, pH adjusters (triethanolamine, citric acid, citric acid, sodium citrate, malic acid, etc.) Sodium Malate, Pmalic Acid, Sodium Fmalate, Succinic Acid, Sodium Succinate, Sodium Hydroxide, Sodium Monohydrogen Phosphate, etc.), Moisturizing Agents (Glycerin, Sorbitol, Propylene Glycol, Butylene Glycol, Hexylene Glycol, Diglycerin , Betaine, glyceres-26, methylgluces-20, etc.), lubricants and the like can be added.
또한, 본 발명의 화장료 조성물은 피부에 필수 영양소를 보조적으로 제공할 수 있는 물질을 추가로 포함하는데, 바람직하게는 천연향, 화장품향, 또는 한약재가 포함되지만 이들에 국한되지 않는 보조제를 함유할 수 있다.In addition, the cosmetic composition of the present invention further includes a substance capable of auxiliaryly providing essential nutrients to the skin, preferably, it may contain a natural scent, a cosmetic scent, or an auxiliary agent including, but not limited to, herbal medicines. have.
본 발명의 화장료 조성물에서 카르본 또는 이의 화장품학적으로 허용 가능한 염의 유효 함량은 특별히 제한되지 않으며, 조성물 전체 중량에 대하여 0.0001 내지 20 중량%로 포함되는 것일 수 있다. 화장료 내에 0.0001 중량% 미만의 카르본 또는 이의 염은 그 용량이 소량이어서 기대하는 개선 효과가 없을 수 있으며, 20 중량% 초과의 카르본 또는 이의 염은 기존에 알려진 독성을 나타낼 수 있다.The effective content of carbon or a cosmetically acceptable salt thereof in the cosmetic composition of the present invention is not particularly limited, and may be included in an amount of 0.0001 to 20% by weight based on the total weight of the composition. Less than 0.0001% by weight of carbon or a salt thereof in the cosmetic may not have an expected improvement effect due to its small dose, and more than 20% by weight of carbon or a salt thereof may exhibit known toxicity.
본 발명의 용어 "향료 조성물"은 향수, 화장품, 입욕제 등의 피부 외용 기제나 식품, 의약품 등에 배합될 수 있고, 배합량은 당업계에 통상적인 기술에 따라, 목적하는 효과를 이루기 위해 적절하게 선택하여 배합할 수 있다.The term "fragrance composition" of the present invention may be formulated as a base for skin external use such as perfume, cosmetics, and bath, or food, pharmaceuticals, etc., and the blending amount is appropriately selected in order to achieve the desired effect according to conventional techniques in the art. Can be blended.
본 발명의 향료　조성물의 제형은 특별하게 제한되지 않지만, 분말, 과립, 액상 스프레이, 고형 및 젤 타입의 제형 중에서 선택된 어느 하나일 수 있다. The formulation of the perfume 　 composition of the present invention is not particularly limited, but may be any one selected from powder, granule, liquid spray, solid and gel type formulations.
상기　향료　조성물은 향수를 포함하는 화장용품, 목욕비누를 포함하는 비누세정용품, 유리 크리너를 포함하는 실내청소용품, 자동차용 방향제를 포함하는 방향용품, 허브타입 입욕제를 포함하는 목욕용품, 문구류를 포함하는 향기상품, 오피스용 방향제를 포함하는 환경용품 또는 합성수지를 포함하는 공업용품을 제조하는데 사용할 수 있다.The 　 perfume 　 composition includes cosmetic products including perfume, soap cleaning products including bath soap, indoor cleaning products including glass cleaners, fragrance products including car air fresheners, bath products including herbal bath products, and stationery It can be used to manufacture a fragrance product, an environmental product including an office fragrance, or an industrial product including a synthetic resin.
본 발명의 향료 조성물은 향료 조성물 전체 중량을 기준으로 할 때 그 유효성분인 카르본을, 본 발명의 향료 조성물이 구체화되는 제품 형태에 따라 0.00001 중량% 내지 10 중량%, 바람직하게는 0.00001 중량% 내지 1.0 중량%, 더 바람직하게는 0.00001 중량% 내지 0.5 중량%의 범위로 함유할 수 있다.The perfume composition of the present invention contains the active ingredient, carbon, based on the total weight of the perfume composition, from 0.00001% to 10% by weight, preferably from 0.00001% by weight, depending on the product type in which the perfume composition of the present invention is embodied. It may contain 1.0% by weight, more preferably in the range of 0.00001% by weight to 0.5% by weight.
상기에서 향료 조성물이 구체화되는 제품 형태는 비누, 화장품, 입욕제, 아로마 오일 등을 포함하며, 구체적으로 바디 로션, 샴푸, 헤어 린스, 헤어 컨디셔너, 헤어 트리트먼트, 발한 억제제, 스킨 로션, 스킨 크림, 방취제, 향수(스프레이제 또는 훈증제), 립스틱, 립크림, 입욕제 등을 포함하나, 이들에 한정되는 것은 아니다.Product types in which the fragrance composition is specified above include soap, cosmetics, bath agents, aroma oils, etc., specifically body lotion, shampoo, hair rinse, hair conditioner, hair treatment, antiperspirant, skin lotion, skin cream, deodorant , Perfume (spray or fumigant), lipstick, lip cream, bath agent, etc., but are not limited thereto.
이들 제품은 혈행 촉진제, 소염제, 보습제, 수렴제, 무기 염, 유기 염, 오일성 성분, 계면활성제, 생약류, 색소, 향료, 황, 탕화(sinter deposit), 살균제 등과 같은 각종 부가제를 함유할 수 있다.These products may contain various additives such as blood circulation accelerators, anti-inflammatory agents, moisturizing agents, astringents, inorganic salts, organic salts, oily ingredients, surfactants, herbal medicines, colors, fragrances, sulfur, sinter deposits, disinfectants, etc. .
특히 본 발명의 향료 조성물은 메이크업 제품, 스킨 로션, 스킨 크림 등의 화장품 제형의 피부 외용제로 사용되는 경우가 일반적일 것인데, 이 경우에는 이들 화장품 제형에 통상적으로 사용되는 성분들을 함유할 수 있다.In particular, the perfume composition of the present invention will generally be used as an external application for the skin of cosmetic formulations such as makeup products, skin lotions, and skin creams. In this case, it may contain ingredients commonly used in these cosmetic formulations.
특히 본 발명의 향료 조성물은 그 유효성분인 카르본이 아토피 피부염 개선 활성을 가진다는 점에서 입욕제에 혼입되어 사용되는 것이 바람직하나. 이 경우 유효성분은 입욕제 총 중량을 기준으로 할 때 바람직하게는 0.00001 중량 내지 1 중량%, 더 바람직하게는 0.0001 내지 0.1 중량%의 범위로 포함될 수 있다. 본 발명의 향료 조성물이 입욕제에 혼입되어 사용되는 경우 그 입욕제는 목욕물에 0.015 내지 15 ppm의 농도로 첨가되어 사용될 수 있다.Particularly, the perfume composition of the present invention is preferably used by being incorporated into a bathing agent in that the active ingredient, carbon, has atopic dermatitis improving activity. In this case, the active ingredient may preferably be included in the range of 0.00001 to 1% by weight, more preferably 0.0001 to 0.1% by weight, based on the total weight of the bath agent. When the fragrance composition of the present invention is incorporated into a bathing agent and used, the bathing agent may be added to the bath water in a concentration of 0.015 to 15 ppm and used.
입욕제는 본 발명의 향료 조성물의 유효성분 이외에 무기 염, 유기산, 오일성 성분 등을 함유할 수 있다.The bath agent may contain inorganic salts, organic acids, oily ingredients, etc. in addition to the active ingredients of the perfume composition of the present invention.
무기염으로서는 염화나트륨, 탄산수소나트륨, 탄산나트륨, 붕사, 황산나트륨, 황화나트륨, 세스퀴탄산나트륨, 질산나트륨, 티오황산나트륨, 폴리인산나트륨, 인산나트륨, 산화칼슘, 산화마그네슘, 탄산칼슘, 탄산마그네슘, 염화칼륨, 황화칼륨 등을 예시할 수 있으며, 이들은 단독으로 또는 2종 이상의 혼합물로서 사용될 수 있다. 이들 무기 염은 입욕제 총 중량을 기준으로 5 중량% 이상, 바람직하게는 10 중량% 이상으로 입욕제에 첨가될 수 있다.As inorganic salts, sodium chloride, sodium hydrogen carbonate, sodium carbonate, borax, sodium sulfate, sodium sulfide, sodium sesquicarbonate, sodium nitrate, sodium thiosulfate, sodium polyphosphate, sodium phosphate, calcium oxide, magnesium oxide, calcium carbonate, magnesium carbonate, potassium chloride, sulfide Potassium and the like may be exemplified, and these may be used alone or as a mixture of two or more. These inorganic salts may be added to the bath agent in an amount of 5% by weight or more, preferably 10% by weight or more, based on the total weight of the bath agent.
유기산으로서는 석신산, 푸마르산, 말산, 타르타르산, 시트르산, 벤조산 등을 예시할 수 있으며, 이들은 단독으로 또는 2종 이상의 혼합물로 사용될 수 있다. 이들 유기산은 입욕제 총 중량을 기준으로 할 때 0.1 내지 50 중량%의 범위로 입욕제에 첨가될 수 있다.As the organic acid, succinic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid and the like can be exemplified, and these may be used alone or in a mixture of two or more. These organic acids may be added to the bath agent in the range of 0.1 to 50% by weight, based on the total weight of the bath agent.
오일성 성분으로서는 왁스, 탄화수소, 고급 지방산, 고급 알콜, 에스테르, 실리콘 오일 등을 들 수 있다.Examples of the oily component include wax, hydrocarbon, higher fatty acid, higher alcohol, ester, and silicone oil.
입욕제는 또한 당해 기술분야에서 통상적으로 사용되는 기타 성분들을 추가로 함유할 수 있다. 이러한 성분들로서는 붕산, 메타규산, 규산 무수물과 같은 무기산; 회향풀, 은행, 생강, 감귤 껍질, 쥐오줌풀 뿌리, 박하, 인삼, 귀리 등의 생약재 분말; 콜타르 염료, 클로로필, 리보플라빈, 사프플라워, 안트라퀴논와 같은 인체에 무해한 것으로 확인된 천연 색소; 비타민 A, 비타민 C, 비타민 D, 비타민 E 등의 비타민류; 황, 운모 분말, 백토 분말, 황토 분말, 쌀겨 탄화물, 살균제, 방부제 등을 들 수 있다.The bath agent may also contain additional ingredients commonly used in the art. Examples of these components include inorganic acids such as boric acid, metasilicic acid, and silicic anhydride; Herbal powders such as fennel, ginkgo, ginger, citrus peel, valerian root, mint, ginseng, and oats; Natural pigments, such as coal tar dye, chlorophyll, riboflavin, safflower, and anthraquinone, which have been found to be harmless to the human body; Vitamins such as vitamin A, vitamin C, vitamin D, and vitamin E; Sulfur, mica powder, clay powder, loess powder, rice bran carbide, fungicides, and preservatives.
이러한 입욕제는 과립, 정제, 액제, 산제 등의 임의의 성상으로 제조될 수 있다.These bathing agents may be prepared in any form such as granules, tablets, liquids, powders, and the like.
본 발명에서 사용되는 용어 "의약외품"은 사람이나 동물의 질병을 진단, 치료, 개선, 경감, 처치 또는 예방할 목적으로 사용되는 물품들 중 의약품보다 작용이 경미한 물품들을 의미하는 것으로, 예를 들어 약사법에 따르면 의약외품이란 의약품의 용도로 사용되는 물품을 제외한 것으로, 사람ㆍ동물의 질병 치료나 예방에 쓰이는 제품, 인체에 대한 작용이 경미하거나 직접 작용하지 않는 제품 등이 포함된다.The term "quasi-drug" as used in the present invention refers to items that are less effective than medicines among items used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing diseases of humans or animals. According to this, quasi-drugs exclude items used for pharmaceutical purposes, and include products used for the treatment or prevention of diseases of humans and animals, and products that have mild or no direct action on the human body.
본 발명의 의약외품 조성물은 알러지성 질환 또는 아토피 피부염의 예방 또는 개선을 목적으로 사용되는 것으로, 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들면, 유연화장수, 영양화장수, 마사지크림, 영양크림, 팩, 마스크팩, 마스크시트, 젤 또는 피부 점착타입 화장료의 제형을 갖는 화장료 조성물일 수 있으며, 또한, 로션, 연고, 겔, 크림, 패취 또는 분무제와 같은 경피투여형 제형일 수 있다.The quasi-drug composition of the present invention is used for the purpose of preventing or improving allergic diseases or atopic dermatitis, and is not particularly limited in its formulation, for example, softening lotion, nutritional lotion, massage cream, nutrition cream, pack , A mask pack, a mask sheet, a gel or a cosmetic composition having a skin adhesive type cosmetic formulation, and may be a transdermal dosage form such as a lotion, ointment, gel, cream, patch, or spray.
또한, 각 제형에 있어서 의약외품 조성물은 다른 성분들을 기타 의약외품의 제형 또는 사용목적 등에 따라 임의로 선정하여 배합할 수 있다. 유효 성분의 혼합양은 사용 목적(억제 또는 완화)에 따라 적합하게 결정될 수 있다. 예를 들어, 점증제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 및 담체 등을 포함할 수 있다.In addition, in each formulation, the quasi-drug composition may be arbitrarily selected and blended according to the formulation or purpose of use of other quasi-drugs. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (inhibition or mitigation). For example, thickeners, stabilizers, solubilizers, conventional adjuvants such as vitamins, pigments and flavors, and carriers may be included.
본 발명의 카르본 또는 이의 염의 함량은 의약외품 조성물의 총 중량을 기준으로 각각 0.0001 내지 20 중량%인 것이 바람직하다. 20 중량%를 초과하는 경우에는 조성물 제조 시 색상 및 안정성이 떨어질 수 있고, 0.0001% 미만의 경우에는 그 작용효과가 미미하다.The content of the carbon or salt thereof of the present invention is preferably 0.0001 to 20% by weight, respectively, based on the total weight of the quasi-drug composition. If it exceeds 20% by weight, color and stability may be deteriorated during the preparation of the composition, and if it is less than 0.0001%, the effect is negligible.
또한, 각 제형의 의약외품 조성물에 있어서, 상기한 필수 성분 이외의 다른 성분들은 제형 또는 사용목적 등에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있다.In addition, in the quasi-drug composition of each formulation, components other than the essential components described above may be appropriately selected and blended by a person skilled in the art without difficulty depending on the formulation or purpose of use.
이하, 실시예를 통하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Below, The present invention will be described in more detail through examples. These examples are for illustrative purposes only, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not construed as being limited by these examples.
실시예 : 비만세포 및 각질형성세포에 카르본(Carvone) 처리 후 염증 관련 사이토카인의 분비 및 발현 평가Example: Evaluation of secretion and expression of inflammation-related cytokines after carvone treatment on mast cells and keratinocytes
1-1. 실험방법1-1. Experiment method
1) 비만세포 세포배양1) mast cell culture
비만세포(rat basophilic leukemia cell line, RBL-2H3)는 ATCC사(Manassas, VA, USA)로부터 구매하여 사용하였다. 10% heat-inactivated FBS(feta bovine serum)(Gibco BRL, USA)과 1% 페니실린(penicillin) 및 스트렙토마이신(streptomycin; Gibco BRL, USA)을 포함한 DMEM(Dulbecco modified eagle medium)(Gibco BRL, USA) 배양액에서 세포를 배양하였다. 세포는 37℃, 5% CO2 조건하에서 배양하여 실험하였다. 비만세포를 10% FBS가 포함된 DMEM에 현탁시킨 후 6 웰 플레이트(well plate; Corning, USA)에 1×106 cells/ml의 세포수가 되도록 분주하였다. Mast cells (rat basophilic leukemia cell line, RBL-2H3) were purchased and used from ATCC (Manassas, VA, USA). DMEM (Dulbecco modified eagle medium) (Gibco BRL, USA) containing 10% heat-inactivated feta bovine serum (FBS) (Gibco BRL, USA) and 1% penicillin and streptomycin (Gibco BRL, USA) Cells were cultured in the culture medium. Cells were cultured under conditions of 37° C. and 5% CO 2 for experiments. The mast cells were suspended in DMEM containing 10% FBS and then dispensed into a 6 well plate (Corning, USA) to a cell number of 1×10 6 cells/ml.
그 후 anti DNP(dinitrophenyl)-IgE(100 ng/ml)로 감작하고 37℃, 5% CO2 인큐베이터에서 24시간 동안 배양하였다. PBS(phosphate buffered saline)로 2회 세척한 다음 DNP-HSA(dinitrophenylated human serum albumin; 100 ng/ml)를 1시간 동안 처리하여 면역반응을 유도하였다. 이때 카르본(Carvone)에 의한 아토피 개선효능을 평가하기 위해 anti DNP(dinitrophenyl)-IgE를 처리하는 동시에 카르본 (100 μM)을 처리하여 24시간 동안 배양한 다음 DNP-HSA로 면역반응을 유도하였다. 음성대조세포의 경우 카르본 대신 DMSO로 처리하여 24시간 동안 배양한 후 DNP-HSA로 면역반응을 유도하였다.Then, it was sensitized with anti DNP (dinitrophenyl)-IgE (100 ng/ml) and incubated in an incubator at 37° C. and 5% CO 2 for 24 hours. After washing twice with PBS (phosphate buffered saline), DNP-HSA (dinitrophenylated human serum albumin; 100 ng/ml) was treated for 1 hour to induce an immune response. At this time, in order to evaluate the atopic improvement effect by carvone, anti-DNP (dinitrophenyl)-IgE was treated and carboxylic (100 μM) was treated and incubated for 24 hours, and then an immune response was induced with DNP-HSA. . In the case of negative control cells, they were treated with DMSO instead of carbon and incubated for 24 hours, and then an immune response was induced with DNP-HSA.
2) 각질형성세포 세포배양2) Cell culture of keratinocytes
각질형성세포(human keratinocyte cell line, HaCaT)는 ATCC사(Manassas, VA, USA)로부터 구매하여 사용하였다. 10% FBS(fetal bovine serum)와 항생제가 들어있는 DMEM 배양액을 사용하여 세포를 배양하였다. 배양 용기는 75T-플라스크(flask)와 6 웰 플레이트를 사용하였으며 5% CO₂가 공급되는 37℃ 배양기에서 배양하였다. 배양액은 3~4일마다 교환해 주며 세포가 과다하게 증식되었을 때는 계대배양 하였다. 분주된 HaCaT 세포(5×105/well)를 24시간 배양한 후 PBS로 세척하였다. 각질형성세포에 면역반응을 유도하기 위해 FBS를 넣지 않은 DMEM 배지에 TNF-α(tumor necrosis factor-α)(10 ng/ml) 및 IFN-γ(interferon gamma)(10 ng/ml)를 함께 처리하여 24 시간동안 배양하였다. 이때 카르본에 의한 면역반응 개선효능을 평가하기 위해 카르본 100 μM을 면역반응 유도물질과 동시에 처리하였으며, 음성대조세포의 경우 카르본 대신 DMSO를 면역반응 유도물질과 동시에 처리하고 24시간 동안 배양하였다.Keratinocytes (human keratinocyte cell line, HaCaT) were purchased and used from ATCC (Manassas, VA, USA). Cells were cultured using a DMEM culture medium containing 10% FBS (fetal bovine serum) and antibiotics. A 75T-flask and a 6-well plate were used as the culture vessel, and cultured in a 37°C incubator supplied with 5% CO2. The culture medium was changed every 3 to 4 days, and when cells were excessively proliferated, they were subcultured. The dispensed HaCaT cells (5×10 5 /well) were cultured for 24 hours and washed with PBS. To induce an immune response to keratinocytes, TNF-α (tumor necrosis factor-α) (10 ng/ml) and IFN-γ (interferon gamma) (10 ng/ml) were treated together in DMEM medium without FBS. And incubated for 24 hours. At this time, in order to evaluate the immune response improvement effect by carbon, 100 μM of carboxylic was treated with the immune response inducing substance at the same time, and in the case of negative control cells, DMSO was treated with the immune response inducing substance instead of carbon and cultured for 24 hours .
3) 히스타민 분비량 측정(Histamine release assay)3) Histamine release assay
면역반응을 유도한 비만세포에서 분비되는 히스타민의 농도를 측정하기 위하여 아이스 배스(ice bath)에서 10분간 정치하여 면역 반응을 종결시킨 후 배양액을 10,000 xg에서 10분간 원심분리한 후, 상층액을 취하여 96-웰 플레이트에 옮겼다. 히스타민 정량은 ENZO사의 히스타민 측정 키트(histamine release assay ELISA kit)를 이용하였으며 인피니트 M200 프로 마이크로플레이트 리더(Infinite M200 pro microplate reader, TECAN) 450nm 파장에서 측정하였다. In order to measure the concentration of histamine secreted from mast cells that induced the immune response, the immune reaction was terminated by standing in an ice bath for 10 minutes, and the culture was centrifuged at 10,000 xg for 10 minutes, and the supernatant was taken. Transferred to a 96-well plate. Histamine was quantified using ENZO's histamine release assay ELISA kit, and was measured at 450 nm wavelength of Infinite M200 pro microplate reader (TECAN).
4) 트리졸 방법(Trizol method)을 이용한 RNA 분리 및 real-time PCR (quantitative reverse-transcription polymerase chain reacion)4) RNA isolation and real-time PCR (quantitative reverse-transcription polymerase chain reacion) using the Trizol method
면역반응을 유도한 비만세포의 상층액을 제거한 후 1 ml의 트리졸을 넣고 2분간 방치한 후 클로로포름(chloroform)을 넣고 10초간 볼텍싱(vortexing)하고 2,400 xg에서 10분간 원심분리한 후, 상층액을 취하여 동량의 이소프로판올(isopropanol)을 혼합하여 흔들어 주었다. 16,000 xg에서 25분간 원심분리하여 상층액을 제거하고 펠릿(pellet)은 DEPC(diethyl pyrocarbonate)-DW 20μl에 녹여 -20℃에 보관하였다가 실험에 사용하였다. RT-PCR은 one-step RT-PCR PreMix kit(iNtRON Biotechnology, Korea)를 사용하여 45℃에서 30분, 94℃에서 5분간 반응시킨 후 94℃에서 30초간 변성(denaturation)시키고, 55℃에서 30초간 어닐링(annealing)시킨 다음, 72℃에서 1분간 신장(extension)시키는 사이클(cycle)을 32회 반복한 뒤, 마지막 신장(extension)은 72℃에서 5분간 수행하고 PiQ SYBR green supermix (Bio-Rad)와 CFX Connect™ Real-Time PCR Detection System (Bio-Rad)을 사용하여 정량적 PCR을 수행하였으며, 이때 사용된 프라이머 서열(primer sequence)은 [표 1]에 제시된 바와 같다.After removing the supernatant of the mast cells that induced the immune response, add 1 ml of trizol, leave for 2 minutes, add chloroform, vortex for 10 seconds, and centrifuge at 2,400 xg for 10 minutes, and then the supernatant The solution was taken, and the same amount of isopropanol was mixed and shaken. The supernatant was removed by centrifugation at 16,000 xg for 25 minutes, and the pellet was dissolved in 20 μl of DEPC (diethyl pyrocarbonate)-DW and stored at -20°C before use in the experiment. RT-PCR was reacted at 45°C for 30 minutes and 94°C for 5 minutes using a one-step RT-PCR PreMix kit (iNtRON Biotechnology, Korea), followed by denaturation at 94°C for 30 seconds, and 30 at 55°C. After annealing for a second, the cycle of stretching at 72°C for 1 minute was repeated 32 times, and the last extension was performed at 72°C for 5 minutes, followed by PiQ SYBR green supermix (Bio-Rad ) And CFX Connect™ Real-Time PCR Detection System (Bio-Rad) were used to perform quantitative PCR, and the primer sequence used at this time is as shown in [Table 1].
[표 1][Table 1]
RT-PCR에 사용된 프라이머 서열Primer sequence used for RT-PCR
Figure PCTKR2020010976-appb-I000003
Figure PCTKR2020010976-appb-I000003
1-2. 실험결과1-2. Experiment result
1) 히스타민 분비량 변화1) Changes in histamine secretion
활성화된 비만세포로부터 탈과립에 의해 분비되는 히스타민에 대한 카르본의 효과를 확인하기 위해 세포배양액으로부터 히스타민의 농도를 효소면역반응법으로 측정하였다. 그 결과, anti DNP(dinitrophenyl)-IgE로 감작하고 DNP-HSA로 면역반응을 유도한 대조세포에서는 정상 비만세포에 비해 히스타민 농도가 유의적으로 증가하였다. 한편, anti DNP(dinitrophenyl)-IgE 및 DNP-HSA에 의한 면역반응을 유도하면서 카르본을 처리한 결과, 히스타민의 농도가 유의하게 감소되었다(도 1).In order to confirm the effect of carbon on the histamine secreted by degranulation from activated mast cells, the concentration of histamine in the cell culture was measured by the enzyme immunoreaction method. As a result, the histamine concentration was significantly increased in control cells sensitized with anti-DNP (dinitrophenyl)-IgE and induced an immune response with DNP-HSA compared to normal mast cells. On the other hand, as a result of treatment with carbon while inducing an immune response by anti-DNP (dinitrophenyl)-IgE and DNP-HSA, the concentration of histamine was significantly reduced (FIG. 1).
2) 비만세포에서의 염증성 사이토카인 생성 변화2) Changes in inflammatory cytokine production in mast cells
anti DNP(dinitrophenyl)-IgE로 감작하고 DNP-HSA로 면역반응을 유도한 대조세포에서는 정상 비만세포에 비해 염증성 사이토카인인 IL-4, IL-13 및 TNF-α의 발현이 유의적으로 증가하였다. 한편, anti DNP(dinitrophenyl)-IgE 및 DNP-HSA에 의한 면역반응을 유도하면서 카르본을 처리한 결과, 면역반응으로 인해 증가된 염증성 사이토카인(IL-4, IL-13 및 TNF-α)의 발현이 모두 유의하게 감소되었다(도 2).In control cells sensitized with anti-DNP (dinitrophenyl)-IgE and induced an immune response with DNP-HSA, the expression of inflammatory cytokines IL-4, IL-13, and TNF-α was significantly increased compared to normal mast cells. . On the other hand, as a result of treatment with carbon while inducing an immune response by anti-DNP (dinitrophenyl)-IgE and DNP-HSA, increased inflammatory cytokines (IL-4, IL-13 and TNF-α) All expressions were significantly reduced (Fig. 2).
3) 각질형성세포에서의 염증성 사이토카인 생성 변화3) Changes in inflammatory cytokine production in keratinocytes
TNF-α 및 IFN-γ로 면역반응을 유도시킨 대조세포에서는 정상 각질형성세포에 비해 염증성 사이토카인인 IL-1β, IL-6 및 IL-8의 발현이 유의적으로 증가하였다. 한편, TNF-α 및 IFN-γ과 함께 카르본을 각질형성세포에 처리한 결과, 면역반응으로 인해 증가된 염증성 사이토카인(IL-1β, IL-6 및 IL-8)의 발현이 모두 유의하게 감소되었다(도 3).In control cells induced immune response with TNF-α and IFN-γ, the expression of inflammatory cytokines IL-1β, IL-6 and IL-8 was significantly increased compared to normal keratinocytes. On the other hand, as a result of treating keratinocytes with keratinocytes with TNF-α and IFN-γ, the expression of inflammatory cytokines (IL-1β, IL-6 and IL-8) increased due to the immune response were all significantly. Decreased (Fig. 3).
이하, 본 발명에 따른 상기 카르본을 유효성분으로 함유하는 의약품, 식품 또는 화장품의 제조예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다. 상기 알러지성 질환 또는 아토피 피부염의 예방 및 치료(또는 예방 및 개선 효과) 효과가 우수한 카르본을 이용하여, 하기와 같은 조성성분 및 조성비에 따라, 제조예 1 내지 3의 의약품, 식품 또는 화장료 조성물을 통상적인 방법에 따라서 제조하였다.Hereinafter, examples of preparation of pharmaceuticals, foods, or cosmetics containing the carbon as an active ingredient according to the present invention will be described, but the present invention is not intended to limit this, but is intended to be described in detail. The pharmaceutical, food, or cosmetic compositions of Preparation Examples 1 to 3 were prepared according to the following composition and composition ratio using carbon having excellent preventive and therapeutic (or preventive and improving effect) effect of the allergic disease or atopic dermatitis. It was prepared according to a conventional method.
[제조예 1] 약학적 조성물의 제조[Production Example 1] Preparation of pharmaceutical composition
<1-1> 산제의 제조<1-1> Preparation of powder
카르본 20 ㎎ Carbon 20 mg
유당수화물 100 ㎎100 mg of lactose hydrate
탈크 10 ㎎Talc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above ingredients were mixed and filled in an airtight cloth to prepare a powder.
<1-2> 정제의 제조<1-2> Preparation of tablets
카르본 10 ㎎10 mg of carbon
옥수수전분 100 ㎎ Corn starch 100 mg
유당수화물 100 ㎎100 mg of lactose hydrate
스테아르산마그네슘 2 ㎎Magnesium stearate 2 mg
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above ingredients, tablets were prepared by tableting according to a conventional tablet preparation method.
<1-3> 캅셀제의 제조<1-3> Preparation of capsules
카르본 10 ㎎10 mg of carbon
미결정셀룰로오스 3 ㎎ Microcrystalline cellulose 3 mg
유당수화물 14.8 ㎎Lactose hydrate 14.8 mg
스테아르산마그네슘 0.2 ㎎Magnesium stearate 0.2 mg
상기의 성분을 혼합한 후, 통상의 캅셀제의 제조방법에 따라서 젤라틴캡슐에 충전하여 캅셀제를 제조하였다.After mixing the above ingredients, the capsules were prepared by filling them into gelatin capsules according to a conventional capsule preparation method.
<1-4> 주사제의 제조<1-4> Preparation of injection
카르본 10 ㎎10 mg of carbon
만니톨 180 ㎎Mannitol 180 mg
주사용 멸균 증류수 2974 ㎎2974 mg of sterile distilled water for injection
인산일수소나트륨 26 ㎎Sodium monohydrogen phosphate 26 mg
상기의 성분을 혼합한 후, 통상의 주사제의 제조방법에 따라 1앰플당(2mL) 상기의 성분 함량으로 제조하였다.After mixing the above ingredients, it was prepared with the above ingredient content per ampoule (2 mL) according to a conventional method for preparing injections.
<1-5> 액제의 제조<1-5> Preparation of liquid formulation
카르본 10 ㎎10 mg of carbon
이성화당 10 ㎎Isomerized sugar 10 mg
만니톨 5 ㎎Mannitol 5 mg
정제수 적량Purified water appropriate amount
레몬향 적량Lemon flavor appropriate amount
상기의 성분을 통상의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 정제수를 가하여 전체 100mL로 조절한 후 멸균시켜 갈색병에 충진하여 액제를 제조한다. The above ingredients are dissolved by adding each ingredient to purified water according to a conventional manufacturing method, added an appropriate amount of lemon flavor, adjusted to 100 mL by adding purified water, sterilized, and filled in a brown bottle to prepare a liquid formulation.
[제조예 2] 건강식품의 제조[Production Example 2] Preparation of health food
<2-1> 건강보조식품의 제조<2-1> Manufacture of health supplement food
카르본 10 ㎎10 mg of carbon
비타민 혼합물 적량Vitamin mixture right amount
비타민 A 아세테이드 70 ㎍Vitamin A acetate 70 ㎍
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎Vitamin B 1 0.13 mg
비타민 B2 0.15 ㎎Vitamin B 2 0.15 mg
비타민 B6 0.5 ㎎Vitamin B 6 0.5 mg
비타민 B12 0.2 ㎍Vitamin B 12 0.2 ㎍
비타민 C 10 ㎎Vitamin C 10 mg
비오틴 10 ㎍Biotin 10 ㎍
니코틴산아미드 1.7 ㎎Nicotinic acid amide 1.7 mg
엽산 50 ㎍Folic acid 50 ㎍
판토텐산 칼슘 0.5 ㎎0.5 mg of calcium pantothenate
무기질 혼합물 적량Suitable amount of inorganic mixture
황산제1철 1.75 ㎎Ferrous sulfate 1.75 mg
산화아연 0.82 ㎎Zinc oxide 0.82 mg
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎Dicalcium phosphate 55 mg
구연산칼륨 30 ㎎Potassium citrate 30 mg
탄산칼슘 100 ㎎100 mg of calcium carbonate
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.The composition ratio of the vitamin and mineral mixture is relatively suitable for health food, but it may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. , Granules can be prepared, and used for preparing health food compositions according to a conventional method.
<2-2> 건강음료의 제조<2-2> Manufacture of health drinks
카르본 10 mg10 mg carbon
비타민 C 15 g15 g of vitamin C
비타민 E(분말) 100 g100 g of vitamin E (powder)
젖산철 19.75 g19.75 g of iron lactate
산화아연 3.5 gZinc oxide 3.5 g
니코틴산아미드 3.5 g3.5 g of nicotinic acid amide
비타민 A 0.2 g0.2 g of vitamin A
비타민 B1 0.25 g0.25 g of vitamin B1
비타민 B2 0.3 g0.3 g of vitamin B2
정제수 정량Purified water quantification
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.After mixing the above ingredients according to a conventional health drink manufacturing method, stirring and heating at 85°C for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 liter container, sealed and sterilized, and then stored in a refrigerator. It is used in the manufacture of health beverage composition.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.The composition ratio is a mixture of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the demand class, the country of demand, and the purpose of use.
[제조예 3] 화장료 조성물의 제조[Production Example 3] Preparation of cosmetic composition
하기에 본 발명의 추출물을 함유하는 화장료 조성물의 제조예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, a preparation example of a cosmetic composition containing the extract of the present invention will be described, but the present invention is not intended to limit it, but is intended to be described in detail.
<3-1> 영양화장수(밀크로션)<3-1> Nutritional lotion (milk lotion)
카르본 2.0 중량%2.0% by weight of carbon
스쿠알란 5.0 중량%5.0% by weight of squalane
밀납 4.0 중량%4.0 wt% beeswax
폴리솔베이트60 1.5 중량%1.5% by weight of polysorbate 60
솔비탄세스퀴올레이트 1.5 중량%1.5% by weight of sorbitansquioleate
유동파라핀 0.5 중량%0.5% by weight of liquid paraffin
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic/Capric Triglyceride 5.0% by weight
글리세린 3.0 중량%3.0% by weight of glycerin
부틸렌글리콜 3.0 중량%Butylene glycol 3.0% by weight
프로필렌글리콜 3.0 중량%Propylene glycol 3.0% by weight
카르복시비닐폴리머 0.1 중량%0.1% by weight of carboxyvinyl polymer
트리에탄올아민 0.2 중량%0.2% by weight of triethanolamine
방부제, 색소, 향료 적량Preservative, color, and fragrance
정제수 to 100 중량%Purified water to 100% by weight
상기의 배합비는 비교적 영양화장수에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. The above blending ratio is a mixture of ingredients suitable for a relatively nutrient lotion in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
<3-2> 유연화장수(스킨로션)<3-2> Flexible lotion (skin lotion)
카르본 2.0 중량 %Carbon 2.0 wt%
글리세린 3.0 중량 %3.0% by weight of glycerin
부틸렌글리콜 2.0 중량 %2.0% by weight of butylene glycol
프로필렌글리콜 2.0 중량 %2.0% by weight of propylene glycol
카르복시비닐폴리머 0.1 중량 %0.1% by weight of carboxyvinyl polymer
PEG 12 노닐페닐에테르 0.2 중량 %PEG 12 nonylphenyl ether 0.2% by weight
폴리솔베이트80 0.4 중량 % Polysorbate 80 0.4% by weight
에탄올 10.0 중량 %Ethanol 10.0% by weight
트리에탄올아민 0.1 중량 %0.1% by weight of triethanolamine
방부제, 색소, 향료 적량Preservative, color, and fragrance
정제수 to 100 중량 %Purified water to 100% by weight
상기의 배합비는 비교적 유연화장수에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. The above blending ratio is a mixture of ingredients suitable for a relatively soft lotion in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
<3-3> 영양크림<3-3> Nutrition cream
카르본 2.0 중량 % Carbon 2.0 wt%
폴리솔베이트60 1.5 중량 % Polysorbate 60 1.5% by weight
솔비탄세스퀴올레이트 0.5 중량 %0.5% by weight of sorbitansquioleate
PEG60 경화피마자유 2.0 중량 %PEG60 hydrogenated castor oil 2.0% by weight
유동파라핀 10 중량 %Liquid paraffin 10% by weight
스쿠알란 5.0 중량 %5.0% by weight of squalane
카프릴릭/카프릭트리글리세라이드 5.0 중량 %Caprylic/Capric Triglyceride 5.0% by weight
글리세린 5.0 중량 %5.0% by weight of glycerin
부틸렌글리콜 3.0 중량 %Butylene glycol 3.0% by weight
프로필렌글리콜 3.0 중량 %Propylene glycol 3.0% by weight
트리에탄올아민 0.2 중량 %0.2% by weight of triethanolamine
방부제 적량Appropriate amount of preservative
색소 적량Appropriate amount of pigment
향료 적량Suitable amount of fragrance
정제수 to 100 중량 %Purified water to 100% by weight
상기의 배합비는 비교적 영양크림에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. The above blending ratio is a mixture of ingredients suitable for a nutritional cream in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
<3-4> 마사지크림<3-4> Massage cream
카르본 1.0 중량 %1.0% by weight of carbon
밀납 10.0 중량 %10.0 wt% beeswax
폴리솔베이트60 1.5 중량 % Polysorbate 60 1.5% by weight
PEG 60 경화피마자유 2.0 중량 % PEG 60 hydrogenated castor oil 2.0% by weight
솔비탄세스퀴올레이트 0.8 중량 %Sorbitansquioleate 0.8% by weight
유동파라핀 40.0 중량 %Liquid paraffin 40.0% by weight
스쿠알란 5.0 중량 %5.0% by weight of squalane
카프릴릭/카프릭트리글리세라이드 4.0 중량 %Caprylic/Capric Triglyceride 4.0% by weight
글리세린 5.0 중량 %5.0% by weight of glycerin
부틸렌글리콜 3.0 중량 %Butylene glycol 3.0% by weight
프로필렌글리콜 3.0 중량 %Propylene glycol 3.0% by weight
트리에탄올아민 0.2 중량 %0.2% by weight of triethanolamine
방부제, 색소, 향료 적량Preservative, color, and fragrance
정제수 to 100 중량 %Purified water to 100% by weight
상기의 배합비는 비교적 마사지크림에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. The above blending ratio is a mixture of ingredients suitable for a massage cream in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
<3-5> 팩<3-5> pack
카르본 1.0 중량 %1.0% by weight of carbon
폴리비닐알콜 13.0 중량 %13.0% by weight of polyvinyl alcohol
소듐카르복시메틸셀룰로오스 0.2 중량 %Sodium carboxymethylcellulose 0.2% by weight
글리세린 5.0 중량 %5.0% by weight of glycerin
알란토인 0.1 중량 %0.1% by weight allantoin
에탄올 6.0 중량 %Ethanol 6.0% by weight
PEG 12 노닐페닐에테르 0.3 중량 %PEG 12 nonylphenyl ether 0.3% by weight
폴리솔베이트60 0.3 중량 %Polysorbate60 0.3% by weight
방부제, 색소, 향료 적량Preservative, color, and fragrance
정제수 to 100 중량 %Purified water to 100% by weight
상기의 배합비는 비교적 팩에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. The above blending ratio is a mixture of ingredients suitable for the pack in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
<3-6> 젤<3-6> gel
카르본 0.5 중량 %0.5% by weight of carbon
에틸렌디아민초산나트륨 0.05 중량 %Sodium ethylenediamine acetate 0.05% by weight
글리세린 5.0 중량 %5.0% by weight of glycerin
카르복시비닐폴리머 0.3 중량 %0.3% by weight of carboxyvinyl polymer
에탄올 5.0 중량 %Ethanol 5.0% by weight
PEG 60 경화피마자유 0.5 중량 % PEG 60 hydrogenated castor oil 0.5% by weight
트리에탄올아민 0.3 중량 %0.3% by weight of triethanolamine
방부제, 색소, 향료 적량Preservative, color, and fragrance
정제수 to 100 중량 %Purified water to 100% by weight
상기의 배합비는 비교적 젤에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. The above blending ratio is a mixture of ingredients suitable for a gel in a preferred embodiment, but the blending ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
상기 배합비는 비교적 화장료 조성물에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 외의 색채 화장품을 포함하는 다양한 용도의 화장품에 적용될 수 있는 것이고, 그 효능에 따라 인체에 얇게 도포하여 바를 수 있는 약제 즉, 연고로 제조에 이용될 수 있으며 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다. The above blending ratio is a mixture of ingredients suitable for a cosmetic composition in a preferred embodiment, but can be applied to cosmetics for various purposes including other colored cosmetics, and a drug that can be applied thinly to the human body according to its efficacy, that is, It can be used for manufacturing as an ointment, and the blending ratio can be arbitrarily modified according to regional and ethnic preferences such as the demand class, the country of demand, and the purpose of use.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.The above description of the present invention is for illustrative purposes only, and those of ordinary skill in the art to which the present invention pertains will be able to understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not limiting.

Claims (9)

  1. 카르본(Carvone) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 치료용 약학적 조성물. A pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis, including carvone or a pharmaceutically acceptable salt thereof as an active ingredient.
  2. 제1항에 있어서,The method of claim 1,
    상기 알러지성 질환은 부종, 과민증(anaphylaxis), 알러지성 비염(allergic rhinitis), 천식(asthma), 알러지성 결막염(allergic conjunctivitis), 알러지성 피부염(allergic dermatitis),　접촉성 피부염, 두드러기, 소양증, 곤충 알러지, 식품 알러지 및 약품 알러지로 이루어진 군에서 선택되는 하나 이상을 포함하는 것을 특징으로 하는 알러지성 질환 또는 아토피 피부염의 예방 또는 치료용 약학적 조성물. The allergic diseases include edema, anaphylaxis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, 　 contact dermatitis, urticaria, pruritus, insects. Allergic disease or atopic dermatitis prevention or treatment pharmaceutical composition comprising at least one selected from the group consisting of allergy, food allergy and drug allergy.
  3. 제1항에 있어서,The method of claim 1,
    상기 유효성분은 IL-4, IL-13, TNF-α, IL-1β, IL-6 또는 IL-8의 발현을 감소시키거나, 히스타민의 분비량을 감소시키는 것을 특징으로 하는 알러지성 질환 또는 아토피 피부염의 예방 또는 치료용 약학적 조성물.The active ingredient is an allergic disease or atopic dermatitis, characterized in that it reduces the expression of IL-4, IL-13, TNF-α, IL-1β, IL-6 or IL-8, or reduces the amount of histamine secretion. Pharmaceutical composition for the prevention or treatment of.
  4. 카르본(Carvone) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 의약외품 조성물. A quasi-drug composition for the prevention or improvement of allergic diseases or atopic dermatitis comprising carvone or a pharmaceutically acceptable salt thereof as an active ingredient.
  5. 카르본(Carvone) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 화장료 조성물. A cosmetic composition for the prevention or improvement of allergic diseases or atopic dermatitis, including carvone or a cosmetically acceptable salt thereof as an active ingredient.
  6. 카르본(Carvone) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 향료 조성물. Fragrance composition for the prevention or improvement of allergic diseases or atopic dermatitis, comprising as an active ingredient carvone or a cosmetically acceptable salt thereof.
  7. 카르본(Carvone) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 개선용 건강기능식품 조성물.A health functional food composition for the prevention or improvement of allergic diseases or atopic dermatitis, including carvone or a food pharmaceutically acceptable salt thereof as an active ingredient.
  8. 카르본(Carvone) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 조성물을 개체에 투여 또는 복용시키는 단계를 포함하는 알러지성 질환 또는 아토피 피부염의 예방 또는 치료 방법. A method for preventing or treating allergic diseases or atopic dermatitis, comprising administering or taking a composition comprising carvone or a pharmaceutically acceptable salt thereof as an active ingredient.
  9. 카르본(Carvone) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 조성물의 알러지성 질환 또는 아토피 피부염의 예방 또는 치료 용도.Carvone (Carvone) or a composition comprising a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of allergic diseases or atopic dermatitis.
PCT/KR2020/010976 2019-08-19 2020-08-18 Composition for prevention or treatment of allergic disease or atopic dermatitis comprising carvone or salt thereof as active ingredient WO2021034080A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190101054A KR102076938B1 (en) 2019-08-19 2019-08-19 Composition including carvone or salt thereof as active ingredients for preventing or treating allergic disease or atopic dermatitis
KR10-2019-0101054 2019-08-19

Publications (1)

Publication Number Publication Date
WO2021034080A1 true WO2021034080A1 (en) 2021-02-25

Family

ID=69515268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/010976 WO2021034080A1 (en) 2019-08-19 2020-08-18 Composition for prevention or treatment of allergic disease or atopic dermatitis comprising carvone or salt thereof as active ingredient

Country Status (2)

Country Link
KR (1) KR102076938B1 (en)
WO (1) WO2021034080A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060054807A (en) * 2004-11-16 2006-05-23 박명호 Cosmetics improving for atopy skin
US20060275516A1 (en) * 2005-06-02 2006-12-07 Ram A N S Compositions and methods for the treatment of allergic rhinitis
JP2010260855A (en) * 2009-04-08 2010-11-18 Lion Corp Agent for removing foreign substance in airway, and composition for removing foreign substance in airway
US20100305214A1 (en) * 2007-09-26 2010-12-02 Aisa Therapeutics Use of a Monoterpene to Increase Tissue Repair
US20140249234A1 (en) * 2011-06-07 2014-09-04 Frederic J. Burns Compositions and Methods for Restoring the Stratum Corneum and Treating Dermatological Diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180128602A (en) 2017-05-24 2018-12-04 한남대학교 산학협력단 Composition for preventing, improving or treating atopic dermatitis comprising juice of radish root as effective component

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060054807A (en) * 2004-11-16 2006-05-23 박명호 Cosmetics improving for atopy skin
US20060275516A1 (en) * 2005-06-02 2006-12-07 Ram A N S Compositions and methods for the treatment of allergic rhinitis
US20100305214A1 (en) * 2007-09-26 2010-12-02 Aisa Therapeutics Use of a Monoterpene to Increase Tissue Repair
JP2010260855A (en) * 2009-04-08 2010-11-18 Lion Corp Agent for removing foreign substance in airway, and composition for removing foreign substance in airway
US20140249234A1 (en) * 2011-06-07 2014-09-04 Frederic J. Burns Compositions and Methods for Restoring the Stratum Corneum and Treating Dermatological Diseases

Also Published As

Publication number Publication date
KR102076938B1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
WO2020218720A1 (en) Composition for preventing or treating muscular disorders or improving muscular functions, containing leonurus japonicus extract or leonurine
WO2018004141A1 (en) Composition having effect of skin moisturization improvement, skin exfoliation, skin elasticity enhancement, erythema inhibition, skin wrinkle alleviation or skin photoaging alleviation, containing, as active ingredient, any one or more selected from group consisting of cymene, behenic acid, 2-methoxynaphthalene, thymol, and salts thereof
WO2020067748A1 (en) Composition having anti-stress, anti-depressant or anxiolytic effect comprising at least one compound selected from the group consisting of undecanal, dodecanal, and pharmaceutically acceptable salts thereof as active ingredient
WO2017213346A1 (en) Composition containing diosmin or salt thereof as active ingredient and having skin moisturizing improvement, skin exfoliation, skin elasticity enhancement, erythema inhibition, skin wrinkle alleviation, or skin photoaging retardation effect
WO2020085826A1 (en) Composition for alleviation of skin irritation induced by environmental pollution factors or for skin protection, containing nutmeg extract or macelignan as active ingredient
WO2021080297A1 (en) Composition containing evening primrose flower extract as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby
WO2020145619A1 (en) Composition for allergy prevention, atopic dermatitis alleviation or skin regeneration, containing, as active ingredient, undecane or undecanal
WO2018062820A1 (en) Composition for preventing hair loss and promoting hair growth, comprising phytoestrogen as an active ingredient
WO2018070705A1 (en) Composition for preventing or treating muscle diseases, containing, as active ingredient, diosmin or pharmaceutically acceptable salt thereof
WO2020130478A1 (en) Anti-allergy, atopic dermatitis alleviation or skin regeneration composition containing jasmone as active ingredient
WO2021034080A1 (en) Composition for prevention or treatment of allergic disease or atopic dermatitis comprising carvone or salt thereof as active ingredient
WO2020032435A1 (en) Hair loss-preventing or hair restoration-promoting composition containing yarayara as active ingredient
WO2021167121A1 (en) Composition for allergy prevention, atopic dermatitis alleviation, or skin regeneration, comprising nonane as active ingredient
WO2021167120A1 (en) Anti-allergy composition for atopic dermatitis alleviation or skin regeneration, containing guaiyl acetate as active ingredient
WO2021034082A1 (en) Composition for preventing or treating allergic diseases or atopic dermatitis, comprising ocimene, camphor, or salt thereof as active ingredient
WO2021029659A1 (en) Composition for preventing or treating allergic diseases or atopic dermatitis comprising ethyl vanillin, suberic acid, thiazole or salt thereof as effective component
WO2019172566A1 (en) Anti-stress agent, anti-depressant or anti-anxiety agent composition containing ionone as active ingredient
WO2018221922A1 (en) Composition for preventing and treating muscle-related diseases, containing coptidis rhizoma extract, and use thereof
WO2017142368A2 (en) Composition for preventing and treating allergic or inflammatory skin disease
WO2021002642A1 (en) Composition for preventing or treating rheumatoid arthritis, comprising snake venom
WO2020256380A1 (en) Composition for skin whitening, comprising carvone or salt thereof as active ingredient
WO2019017677A2 (en) Composition comprising citral as effective ingredient for exhibiting effect of muscle strengthening, muscle enhancement, muscle differentiation, muscle regeneration, or sarcopenia suppression
WO2016190689A2 (en) Composition for preventing, alleviating or treating muscle diseases or improving muscular function
WO2019083287A2 (en) Composition comprising phellandrene as active ingredient for preventing hair loss or stimulating new hair growth
WO2012096463A2 (en) Composition containing a mixed herbal extract as an active ingredient for preventing and improving allergic or non-allergic skin disease, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20854372

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20854372

Country of ref document: EP

Kind code of ref document: A1